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ABSTRACT 
Breast cancer is the most common malignancy among women. It remains a major 
cause of mortality, although the five-year survival of breast cancer patients is about 
90%. To aid in the clinical treatment decisions, clinical factors and biomarkers are 
utilized to predict the behaviour and prognosis of breast cancer. Traditionally such 
prognostic factors have been the size and stage of the tumour, hormone receptor 
expression, the amplification status of Her2 oncogene and the proliferation activity 
of the tumour cells. 
The purpose of this study is to investigate regulatory proteins of the metaphase-
anaphase transition of the cell division and evaluate their potential value in 
predicting the prognosis of breast carcinoma patients. The study is based on 1135 
breast cancer patients with a maximum follow-up time of 22 years. The tissue 
material was collected into tissue microarrays and the protein expressions were 
analysed with immunohistochemical and immunofluorescence methods.  
Securin, PTTG1IP, separase and SA2 are proteins involved in the regulation of 
the cell cycle. In this study, the immunohistochemical expression of these proteins 
in breast cancer tissue was examined. The changes in the expression profile were 
then used to estimate their prognostic value. Securin overexpression alone predicted 
a 2.4-fold risk of breast cancer death (p>0.001).  Combined with the other studied 
cell-cycle proteins, this risk was emphasized. A model combining securin, separase 
and axillary lymph node status increased the risk of breast cancer death 6.2-fold (p 
0.0006, CI 3.2-82.6).  In addition, cytoplasmic securin expression was associated 
with triple negative subtype of breast cancer.  
Based on this study securin-related cell cycle proteins are promising new 
candidates as biomarkers for breast cancer prognosis. 
KEYWORDS: Breast cancer, prognosis, cell cycle, securin, PTTG1IP, separase, 
SA2  
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TIIVISTELMÄ 
Rintasyöpä on naisten yleisin syöpä. Viiden vuoden jälkeen sairastuneista naisista 
elossa on n. 90%. Hyvistä hoitotuloksista huolimatta rintasyöpään liittyy siis 
edelleen huomattavaa kuolleisuutta. Rintasyövän käyttäytymisen ennustaminen on 
perinteisesti perustunut kasvaimen kokoon, taudin levinneisyyteen, hormoni-
reseptorien ja Her2-onkogeenin ilmentymiseen syöpäsoluissa sekä kasvainsolujen 
jakautumisaktiivisuuteen. 
Tämän tutkimuksen tarkoituksena on selvittää uusia rintasyövän taudinkulkuun 
ja potilaiden ennusteeseen vaikuttavia tekijöitä. Tutkimus perustuu yhteensä 1135 
rintasyöpäpotilaan aineistoon ja enimmillään 22 vuoden seuranta-aikaan. Potilaiden 
kudosnäytteistä valmistettiin monikudosblokit, joita tutkittiin immunohistokemial-
lisin ja immunofluoresenssi-menetelmin. 
Sekuriini, PTTG1IP, separaasi ja SA2 ovat solunjakautumisen säätelyyn osallis-
tuvia proteiineja. Tutkimuksessa määritettiin näiden proteiinien immunohistoke-
miallista ilmentymistä rintasyöpäkudoksessa sekä värjäytymisprofiilin muutosten 
vaikutusta potilaiden ennusteeseen. Sekuriinin yli-ilmentyminen yksinään ennusti 
2.4-kertaista rintasyöpäkuoleman riskiä (p>0.001). Yhdistettynä muihin solun-
jakautumisen säätelyyn osallistuviin proteiineihin riski korostui. Sekuriini, separaasi 
ja kainaloimusolmukestatus ennustivat 6.2-kertaista riskiä (p 0.0006, CI 3.2-82.6). 
Sekuriinin ilmentyminen solun sytoplasmassa liittyi voimakkaasti huonoennus-
teiseen kolmoisnegatiiviseen rintasyöpään. 
Tutkimuksen perusteella sekuriiniin liittyvät solunjakautumista säätelevät 
proteiinit ovat lupaavia tulevaisuuden biomarkkereita rintasyövän ennusteen-
arviointia ja yksilöllisiä hoitopäätöksiä varten. 
AVAINSANAT: rintasyöpä, ennuste, solunjakautuminen, sekuriini, PTTG1IP, 
separaasi, SA2 
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1 Introduction 
Cancer progression is dependent on sustaining proliferative signalling, evading 
growth suppressors and the immune system, resisting cell death, enabling replicative 
immortality, inducing angiogenesis and activating invasion and metastasis (Hanahan 
and Weinberg 2011). Loss of proliferative control is a common feature of cancer 
caused by cell cycle dysregulation (Williams and Stoeber 2012). The controlled 
maintenance, release and dismantling of sister chromatid cohesion has been 
described as one of the key elements in ensuring the normal progression of the cell 
cycle. The distribution of DNA during meta-phase/anaphase transition is one of the 
critical events of the cell cycle controlled by an active process involving a network 
of regulatory proteins, the function of many of these presently poorly understood. 
Mistakes in this process may lead to genetic instability, characterized by an 
increasing number of genetic alterations, the loss of cell cycle control and DNA 
repair, promoting tumorigenesis (Hanahan and Weinberg 2011).  
Proliferation has been shown a strong indicator of disease progression and out-
come in several malignancies, including breast cancer. Mitotic functions are also 
exploited in cancer treatment. Blocking mitotic exit has also been speculated as an 
efficient anticancer strategy. Disturbing the cellular functions during cell cycle may 
lead to abnormal microtubule assembly or spindle assembly and cause cell cycle 
arrest in cancer cells (Dominguez-Brauer et al 2015). 
Cell division is a tightly controlled process, in which interactions between 
protein cascades manage the equal division of genetic material to the daughter cells. 
Errors in this process may lead to cell death but also to aneuploidy and an escape 
from checkpoint control (Giam and Rancati 2015, Potapova and Gorbsky 2017). The 
spindle assembly checkpoint delays the onset of meta-phase until all the chromatids 
have been properly aligned in anaphase. This delay is provided by a protein complex 
called anaphase promoting complex/cyclosome (APC/C). Once the chromatids are 
properly aligned, activation of APC/C leads to the destruction of securin, initiating 
the protein cascade and leading to the separation of sister chromatids.  
Presently, clinical and histological features and a small set of molecular 
biomarkers are utilized to direct the management of breast cancer patients (Rakha 
and Ellis 2011, Goldhirsch et al 2013). Molecular techniques have shown potential 
Introduction 
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in research approach but their actual role in clinical practice is still limited 
(Goldhirsch et al 2013). Biology-driven research applied in immunohistochemical 
detection of biomarkers still provides a reliable, fast and inexpensive method for 
clinical use (Fumagalli et al 2012). The last decades have emphasized the need for 
accurate prognostic and predictive information for individualized treatment of breast 
cancer since molecular taxonomy has revealed the molecular heterogeneity of the 
disease (Januškevičienė and Petrikaitė 2019). 
The present study focuses on immunohistochemical identification of novel, 
clinically applicable biomarkers, securin, PTTG1IP, separase, SA2, with potential to 
aid in personalized treatment decisions in breast cancer.  
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2 Review of the Literature 
2.1 Clinical features of breast cancer 
2.1.1 Incidence 
Breast cancer is the most common malignancy and cause of cancer deaths among 
women in both Finland and worldwide. According to Finnish Cancer Registry every 
8th Finnish woman will be diagnosed with breast cancer during her lifespan and the 
incidence has more than tripled during the last 50 years (Finnish Cancer Registry 2019). 
In 2017, 4947 new cases of breast cancer were diagnosed in Finland, comprising one 
third of all malignancies among women. In the same year, 923 women died of breast 
cancer accounting for approximately 15% of all female cancer deaths. Worldwide, 
breast cancer comprises 12% of new malignancies among women (Ferlay J et al 2018).  
 
2.1.2 Etiology 
Breast cancer is a multifactorial disease (Lakhani et al 2012). The development of 
breast cancer is hormone-dependent and associated with life-long exposure to 
oestrogen. Thus, a substantial risk factor is the exposure to both endogenous and 
exogenous sex hormones, including early menarche, nullipara, late pregnancies and 
menopause (Barlow et al 2006). Recent and long-term menopausal hormone 
replacement therapy also increases the risk of breast cancer, especially when 
combined with progestin (Collaborative Group on Hormonal Factors in Breast 
Cancer 2019). Risk of breast cancer increases with age (Barlow et al 2006). Body 
mass index has been shown to associate with the risk of breast cancer, especially 
among postmenopausal women (Luo et al 2019). Lifestyle features associated with 
obesity, i.e. the lack of physical activity and high energy nutrition (Chlebowski 
2013), as well as alcohol abuse (Seitz et al 2012) and smoking (Gaudet et al 2017) 
have also been presented as risk factors for breast cancer.  
There are also known genetic risk factors for breast cancer. The most common 
dominant mutations are in the DNA repair genes BRCA1 and BRCA2. The incidence 
of inactivating, clinically relevant BRCA-mutations in Europe is 0.12–0.32% and, 
Review of the Literature 
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in addition to breast cancer, they are also associated with pre-disposition to other 
malignancies, such as ovarian or fallopian carcinomas (Lakhani et al. 2012, Paul and 
Paul 2014). By 70 years of age, carriers of a mutated BRCA1 gene have a 65% risk 
and carriers of a mutated BRCA2 gene a 45% risk of developing breast cancer (Paul 
and Paul 2014). In addition, increased risk of breast cancer may be associated with 
other syndromes with generally increased risk of malignancies such as Li-Fraumeni 
syndrome (TP53) or Cowden’s syndrome (PTEN) (Paluch-Shimon et al 2016). 
2.1.3 Classification 
Invasive breast cancer is not a single entity. It can be divided into several different 
histological entities based on the morphology and the molecular profile of the tumour 
(Lakhani et al. 2012). The most common subtype is called invasive ductal or 
carcinoma of no special type (carcinoma NST) (Fig. 1). This subtype comprises 40-
70% of all breast cancer cases. The second most common subtype (5–15% of breast 
cancer cases) is invasive lobular breast cancer, characterized by a growth pattern with 
strand-like infiltration of cancer cells caused by the loss of E-cadherin expression. The 
remaining cases represent rare subtypes, e.g. tubular, mucinous or papillary 
carcinomas, each comprising 1–2% of all breast carcinomas. The morphological 
features of the carcinomas are routinely scored from haematoxylin and eosin (H&E) -
stained histological specimen and combined into histological grades I–III (Figure 1). 
 
Figure 1   Microphotographs representing morphology of ductal breast carcinoma comprising 
infiltration of cancer cells in tubular structures. Low (grade I) (A), moderate (II) (B), and 
high (III) (C) histological grades are characterized by the extent of tubule formation, 
nuclear atypia and mitotic activity. 
2.1.4 Molecular subtyping of breast cancer 
In addition to the traditional histological subgroups, breast cancer is classified 
according to molecular expression patterns established based on gene-expression 
experiments (Perou et al 2000, Sørlie et al 2001, van 't Veer, L J et al 2002). The 
Heli Repo 
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most established division is into the intrinsic subtypes luminal A, luminal B, human 
epidermal growth factor 2 (HER2) –enriched and basal-like carcinomas. As the gene 
expression –based classification can be expensive and time consuming in clinical 
practice, the St Gallen International Breast Cancer Conference Expert Panel has 
presented surrogate markers, which may be used for the same purpose (Goldhirsch 
et al 2011, Coates et al 2015) (Table 1). 
Table 1  Summary of surrogate markers for intrinsic classification of breast carcinomas. 
Subtype Criteria 
Luminal A *ER+, PR+, HER2 -, Ki-67 < 20-29% 
Luminal B (HER2-negative) ER+, HER2 -, Ki-67 > 20-29% or PR < 10% 
Luminal B (HER2-positive) ER+, HER2+, any Ki-67, any PR  
HER2-positive HER2+, ER-, PR- 
Triple-negative ER-, PR-, HER2- 
*Abbreviations used in this table: ER oestrogen receptor, PR progesterone receptor, HER2 human 
epidermal growth factor 2, Ki-67 proliferation marker 
2.1.5 Clinical prognostic and predictive markers of breast 
cancer 
The histological diagnosis of breast cancer contains only a limited amount of 
information on the progression and the prognosis of the disease. For informed 
decisions on treatment of an individual patient additional information is required. 
For this purpose, there are several well established clinical, histopathological and 
molecular prognostic and predictive markers.  
Significant prognostic information on the expected course of the disease can be 
obtained from the clinical prognostic features. These include tumour size, axillary 
lymph node status and the presence of distant metastases. These features are evaluated 
individually and combined into the staging of the disease in the tumour, lymph node 
and metastasis (TNM) classification (Senkus et al 2015, Cserni et al 2018). 
The histopathological characteristics providing evidence on the behaviour of the 
disease include the extents of tubule formation, nuclear atypia and mitotic activity 
(Fig. 1). Other morphological features, such as the histological type, specific growth 
pattern, cellular differentiation, the extent of in situ –component and presence of 
lympho-vascular invasion are also taken into consideration in treatment decisions 
(Senkus et al 2015). 
Prognostic and predictive biomarkers of breast cancer include 
immunohistochemical detection of oestrogen (ER) and progesterone (PR) receptors, 
HER2 amplification status and the extent of cell proliferation evaluated using e.g. 
Ki-67 –antibody. After screening with IHC, HER2 amplification is further verified 
using in situ hybridization (Wolff et al 2013). These results are used as the surrogate 
criteria for the intrinsic classification as outlined in chapter 2.1.4.   
Review of the Literature 
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Recently, markers of the tumour microenvironment, tumour stroma and 
inflammatory cells have been added to the analysis of breast cancer development and 
prognosis. For instance, analysis on the nature of tumour infiltrating lymphocytes 
(TILs) (Loi et al 2014) and the expression of the programmed death -ligand 1 (PD-
L1) (Bertucci and Gonçalves 2017) have shown to work as tools for the prognostic 
evaluation of breast cancer.  
2.1.6 Clinical management of breast cancer 
The treatment decisions of an individual patient are based on so called triple-
diagnostics involving clinical, radiological and histopathological information. 
Treatment decisions are based on international and national guidelines, provided by 
expert panels (Table 2). Surgery is still the gold standard of treatment of localized 
breast cancer, although it is increasingly preceded by neoadjuvant treatments. After 
primary surgery the decision of adjuvant therapy involving radiation or cytotoxic 
systemic therapies is made. The management of metastatic disease is often still 
challenging. Recent discoveries such as immunotherapy targeting specific molecular 
pathways and combinations of chemotherapy and biological treatments are 
providing new tools for the treatment of these patients (Senkus et al 2015, Curigliano 
et al 2017). Particularly, in the aggressive triple-negative subgroup anti-PD-L1 
treatments are showing promising results (Lazarus et al 2019). 
Table 2  The adjuvant treatment of breast cancer after primary surgery. 
Low risk of recurrence  
Tumour size <10mm, lymph node negative, 
ER+, PR+, HER2 - Either no adjuvant therapy or endocrine therapy 
Intermediate risk of recurrence 
Tumour size 11–20mm, lymph node negative, 
grade I–II ER+, PR+, HER2- Endocrine therapy 
Tumour size 11–20mm, lymph node negative, 
grade II–III ER+, PR+, HER2- Chemotherapy and endocrine therapy 
High risk of recurrence 
Age <35yrs, Tumour size >20mm, lymph node 
positive, all triple-negative*, all HER2+*  
Chemotherapy and endocrine therapy if ER ≥ 1% 
HER2+: chemotherapy and trastuzumab 
Modified from the Finnish Breast Cancer Group 2019 guidelines 
* apart from tumour size <5mm, lymph node negative 
2.2 Cell proliferation 
2.2.1 The cell cycle 
The maintenance of life is mainly owed to the controlled maintenance of 
chromosomal integrity during the cell division of the cell cycle. Both the genetic 
Heli Repo 
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information in chromosomes and the cell organelles are doubled during the cell cycle 
to ensure an identical copy or the original cell.   
During the cell cycle, the chromosomes are duplicated at the S-phase. The cell 
division the occurs during the M-phase. Since the eukaryotic cells require time to 
transition between these two active phases, there are two gap phases in the cell cycle 
(Figure 2). The first gap (G1) phase takes place at the beginning of each cell cycle, 
after M phase has finished. The second gap (G2) happens between S phase and M 
phase, allowing the cell time to prepare for cytokinesis at the end of M phase. The 
gap periods also allow the cell to perform the necessary checkpoint control to assure 
that the cell is completely prepared for correct division for safe progression to the 
next phase. (Malumbres and Barbacid 2009, McIntosh et al 2012) 
Not all cells take part in the cell cycle. Some cells, such as neurons, are in a 
permanently and irreversibly located in G0 state. In some cells, the G0 state is 
transient and the cell returns to the cycle dependent on specific signalling, e.g. 
phosphorylation in case of retinoblastoma protein.  (Ren and Rollins 2004) 
 
Figure 2  The cell cycle consists of four phases named G1 (gap 1), S (synthesis), G2 (gap 2) and 
M (mitosis). The transition between phases is controlled by cyclin-dependent kinases 
(CDKs). 
Review of the Literature 
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2.2.2 The control of the cell cycle 
The control of the cell cycle is performed by a complex network of protein 
interactions and feedback signalling. The feedback signals function as biochemical 
switches, triggering or inhibiting the surrounding processes. The main regulators of 
the cell cycle are the interactions between cyclins, cyclin-dependent kinases (CDK) 
and CDK-inhibitors, proteins synthetized and degraded in a highly stable manner at 
different phases of the cell cycle. (Malumbres and Barbacid 2009) 
The progression of the cell cycle requires that cyclins are activated by forming 
complexes with CDKs (Fig. 2). The active cyclins can be divided into four different 
classes, named after the period of the cell cycle during which they are active. Thus, 
the G1, G1/S, S and M cyclins are active during the G1, late G1, S and M phases, 
respectively. The full activity of the cyclin-CDK –complex is only achieved after 
phosphorylation by a CDK-dependent kinase. (Malumbres and Barbacid 2009) In 
addition to cyclins, specific inhibitory proteins are known to control the cell cycle 
progression (Besson et al 2008). 
2.2.3 Mitosis 
The mitoses of the cell cycle can be divided into five stages: prophase, prometaphase, 
metaphase, anaphase and telophase (Figure 3). 
At prophase, DNA replication is complete, and the sister chromatids are held 
together by catenation of the DNA and cohesin rings. The cohesin ring is 
multiprotein complex, consisting of four different subunits. In mammalian cells 
these proteins are structural maintenance of chromosomes proteins 1 and 3 (SMC1, 
SMC3), double-strand-break repair protein 21 (Rad21) and stromal antigens 1 or 2 
(SA1/SA2) (Losada 2014). During prophase most of cohesin encircling the sister 
chromatid arms is removed by a process controlled by Aurora B and polo-like kinase 
1 (Plk-1) in a phosphorylation related manner (Gimenez-Abian et al 2004). The 
cohesin at the centromeres is protected from removal by a shugosin (McGuinness et 
al 2005). 
Further, during prophase the duplicated centrosomes move to opposite poles and 
begin to form the mitotic spindle, still leaving the nuclear envelope intact. At 
prometaphase, the nuclear membrane is dissolved and the sister chromatids, attached 
by cohesin at the centromeres and loosely at the chromatid arms, begin to assemble 
to the equator of the cell, guided by the microtubules of the mitotic spindle. At 
metaphase the sister chromatids are aligned between the centrosomes, attached from 
the kinetochores by the microtubules. (McIntosh et al 2012) 
Heli Repo 
 20
 
Figure 3  Mitosis consists of five phases, each with distinct events leading to formation of identical 
daughter cells. Prometaphase is not illustrated in this image. 
The metaphase to anaphase transition is a point of no return. The cohesion be-tween 
sister chromatids is dissolved allowing the chromosomes to be pulled by the spindle 
microtubules towards the opposite poles (McIntosh et al 2012). This event depends 
on the cell passing quality control at the spindle assembly checkpoint (SAC). A key 
switch for this is the activation of anaphase-promoting complex/cyclosome (APC/C) 
by cell division cycle protein 20 (CDC20) (Lara-Gonzalez et al 2012, Musacchio 
2015). Activation of this complex leads to the degeneration of cyclin B and the 
inactivation of CDK1 initiating sister chromatid separation (Musacchio 2015). 
Before anaphase, the sister chromatids are bound together by the remains of the 
cohesin rings. Separase, the protein required for the removal of cohesin rings are 
kept inactive by securin, preventing the cleavage of cohesin and the premature 
separation of the sister chromatids (Ciosk et al 1998) (Figure 4). At SAC, the 
activation of APC/C leads to ubiquitinylation and, eventually, the degradation of 
securin (Shirayama et al 1999), releasing the activated separase. The actual release 
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of the sister chromatids occurs, when separase in turn cleaves the Rad21 portion of 
cohesin from both the centromeres and the residual from chromosome arms 
(Uhlmann et al 1999, Waizenegger et al 2000, Hauf et al 2001, Gimenez-Abian et al 
2004), releasing the sister chromatids. Cohesin cleavage is essential for the normal 
progression of mitosis (Hauf et al 2001). At the same time, release of securin from 
separase leads to autocatalytic destruction of separase (Waizenegger et al 2000). 
 
Figure 4  Transition from metaphase to anaphase involves the sequential activation and 
inactivation of APC/C, CDC20, securin, separase and cohesin. 
At the end of anaphase, the separated sister chromatids are then pulled to the opposite 
sides of the mitotic spindle by the tension caused by the microtubules (McIntosh et 
al 2012). At telophase the separated chromosomes arrive at the poles of the mitotic 
spindle and decondense and the nuclear envelope begins to reconstruct. Finally, at 
cytokinesis the cytoplasm and the cell organelles are divided into two daughter cells, 
both with a single nucleus (Pollard 2009). 
2.2.4 Cell cycle checkpoints 
Maintaining the accuracy of the DNA replication and the proper alignment and 
separation of the sister chromatids is ensured by specific checkpoints. Each 
checkpoint serves as a pathway where the cell cycle progression may be halted in 
case the specific conditions of the cell cycle are not met. The checkpoints are named 
after their location during the cell cycle as G1, G2/M and the spindle assembly 
checkpoint (SAC). 
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2.2.4.1 G1 (restriction) checkpoint  
The G1 checkpoint prevents the cell from initiating the cell cycle unless the 
surrounding environment is favourable. This occurs as a two-step process, the first 
step taking place early in G1 ensuring that enough growth factor signalling is present. 
This checkpoint is controlled by the phosphorylation of the retinoblastoma tumour 
suppressor (Rb) and is mediated by the G1 cyclins. The second step takes place in 
late G1, close to S phase, regulating that the nutritional requirements are present. A 
focal point for this is the function of mammalian target of rapamycin (mTOR), with 
additional guidance from growth factors such as insulin, insulin like growth factor 1 
and platelet derived growth factor.  If the requirements are not met, a normal cell 
will enter quiescence (G0) instead of dividing.  (Foster et al 2010) 
2.2.4.2 G2/M transition checkpoint 
The G2/M checkpoint prevents the diving cell from progressing into mitosis before 
identifying and repairing defected DNA after replication. If this checkpoint is 
defective, G2/M transition occurs despite DNA damage leading to apoptosis and cell 
death. The activity of the cyclinB-CDK1 complex is pivotal in regulating the G2-
phase transition wherein CDK1 is maintained in the inactive phase. (Malumbres and 
Barbacid 2009)  
2.2.4.3 Spindle assembly checkpoint 
The spindle assembly checkpoint (SAC) takes place at the metaphase-anaphase 
transition with the purpose to prevent premature sister chromatic separation. A single 
misaligned chromosome or unattached microtubule is enough to trigger the SAC and 
halt cell cycle progression until all the chromosomes are properly aligned (Rieder et 
al 1995). The checkpoint proteins are located at the kinetochore (Rieder et al 1995) 
and the function of the checkpoint is partly mediated by the tension at the kinetochore 
(Shannon et al 2002).  
Whereas the G1 and G2/M checkpoints are based on the cyclin-CDK interactions 
and protein phosphorylation, SAC is driven by protein destruction (Lara-Gonzalez 
et al 2012). The gatekeeper of this process in the anaphase promoting 
complex/cyclosome (APC/C), a member of the ubiquitin ligase enzymes. The 
APC/C functions as a catalyst, initiating ubiquitinylation and thus the destruction of 
other proteins (Lara-Gonzalez et al 2012). This enzyme function is activated by the 
binding of CDC20 to APC/C, creating the APC/CCDC20 complex (Lara-Gonzalez et 
al 2012, Musacchio 2015). This event also involves complex regulation by additional 
proteins, such as mitotic arrest deficiency 2 (Mad2), budding uninhibited by 
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benzimidatsoles 1 (Bub1) and Aurora kinase B, which are also involved in the 
activation (Musacchio 2015).  
Once all the chromosomes are properly aligned and the mitotic spindle is 
properly attached, the amount of Mad2 at the kinetochores is radically reduced 
(Niault et al 2007). Activation of the APC/CCDC20 complex triggers cyclin B and 
securin in initiating the mitotic exit (Shirayama et al 1999, Musacchio 2015). 
Ubiquitinylation and degradation of securin, in turn, releases separase which initiates 
the dissociation of sister chromatids by cleaving the cohesin complex (Luo and Tong 
2018). 
2.2.5 Errors in mitosis 
If the control for the cell cycle is disrupted, either by delays in the cell division or 
defects in the cell cycle checkpoints, missegregation of chromosomes may occur 
(Potapova and Gorbsky 2017). In missegregation there is a possibility that the 
chromosomal material is only doubled but not distributed into separate daughter cells 
or the distribution is otherwise unequal resulting in an abnormal chromosome 
number. The consequences to the cell vary from insignificant to catastrophic, 
depending on the nature and degree of the genetic error and the role of the cell in the 
organism (Giam and Rancati 2015). In normal cells, a p53-dependent surveillance 
system is responsible for detecting the abnormal chromosome content and halting 
the cell cycle and causing cell death or senescence (Thompson and Compton 2010). 
In malignancy, however, the p53 is often defective, halting this protective process. 
Errors in the mitotic process predispose cells to the loss of tumour-suppressor 
genes, chromosomal instability, aneuploidy and carcinogenesis. However, the 
effects of aneuploidy may be complex and have both pro- and anti-cancerous effects. 
More than 60% of cancers exhibit aneuploidy with variation between tumour types 
and locations (Duijf et al 2013). Chromosomal instability is the cause for different 
subclones of cancer cells in a single tumour i.e. intratumour heterogeneity (Andor et 
al 2017). The accumulating genomic alterations may also give rise to tumour specific 
antigens, neoantigens, which are highly immunogenic and can be targeted by 
immunotherapy (Desrichard et al 2016). 
A low level of chromosomal instability may provide an evolutionary edge but 
eventually the disarray may prove lethal for the cell (Andor et al 2017). Thus, 
intermediate levels of aneuploidy may be associated with a poor prognosis, but when 
taken to extreme levels the result may be adverse (Andor et al 2017). This may be 
exploited in cancer treatment. The DNA-damaging agents, such as cisplatin or DNA 
damage repair inhibitors, such as PARP (Poly(ADP-ribose)polymerase) inhibitors 
cause cell death by inducing DNA damage and inhibiting the repair processes, 
leading to an unsustainable level of chromosomal damage (Oliver et al 2010, 
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Livraghi and Garber 2015) Causes for the increased mitotic infidelity in 
chromosomal instability and aneuploidy include impaired sister chromatid cohesion, 
issues with mitotic timing, errors in the formation of the mitotic spindle or faulty 
double-strand break repair (Thompson et al 2010). One significant source of 
aneuploidy in tumour cells is delay or arrest at metaphase. Normally cells are halted 
in metaphase for only a few minutes, followed by the rapid onset of anaphase. In 
cancer, anaphase onset may be delayed at the metaphase-anaphase checkpoint 
because of the failure of one or more chromosomes to align in a timely manner. In 
the clinical setting, this phenomenon is being applied in antimitotic chemotherapy 
drugs targeting genomic instability (Yamada and Gorbsky 2006). Microtubule 
inhibitors, such as taxans, are used to induce mitotic arrest and prodding the cancer 
cells towards cell death instead of mitosis (Yamada and Gorbsky 2006).  
2.3 Review of securin, PTTG1IP, separase and 
SA2 
2.3.1 Securin 
2.3.1.1 Securin/PTTG1 in normal cells 
Securin, the protein product of the pituitary tumour-transforming gene 1 (Pttg1) was 
originally characterized in rat pituitary tumour cell line as a novel protein capable of 
transforming normal rat pituitary cells into tumour cells (Pei and Melmed 1997). 
Almost simultaneously the human homologue of securin was then cloned from 
human foetal liver (Zhang et al 1999) and Jurkat cells (Dominguez et al 1998). High 
securin expression was also detected in human adult testis and thymus (Dominguez 
et al 1998, Zhang et al 1999) and placenta (Dominguez et al 1998). In several other 
tissues such as colon, small intestine, brain, lung, pancreas, ovary, peripheral blood 
leucocytes and foetal liver the expression of PTTG1 was found to be low or 
undetectable (Dominguez et al 1998, Zhang et al 1999). Even in the highly securin-
expressing normal tissues, the expression levels were generally still lower than in 
carcinoma cell lines from both solid tumours and hematopoietic neoplasia 
(Dominguez et al 1998, Zhang et al 1999). The tumour transforming properties of 
PTTG1 have also described both in vitro and in vivo in a mouse xenograft model 
(Dominguez et al 1998, Zhang et al 1999).  
Securin expression was originally associated with mitosis and the cell cycle 
when identified as a substrate for APC/C and detected to be co-immunoprecipitated 
with the known cell cycle control protein separase (Zou et al 1999). The expression 
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of securin rises in the cell during the onset of S phase and rapidly declines after a 
peak in the G2-M phases (Zou et al 1999).  
It has been speculated that the subcellular localization is critical for the cellular 
function of securin. Securin is required in the nucleus to prevent the premature 
activation on separase (Ciosk et al 1998). Nuclear proteins are synthesized in 
cytoplasm and transported to nucleus via the nuclear pore complex. Typically, this 
transport requires nuclear localization signal (NLS). Securin lacks a nuclear location 
signal but its relatively small 22kDa size, should allow diffusion across the nuclear 
pore complex (Chien and Pei 2000). However, a binding factor of securin, pituitary 
tumour-transforming gene 1 interacting protein (PTTG1IP), has been found to 
participate in the nuclearization of securin (Chien and Pei 2000, Vlotides et al 2007). 
In human tissues, securin has most commonly been reported as both cytoplasmic 
and nuclear (Dominguez et al 1998) in benign tissues, such as normal endometrium 
(Kim et al 2008) as well as in malignant cells of e.g. gliomas (Salehi et al 2013) and 
gastric carcinomas (Xu et al 2016). In normal oesophageal squamous epithelium 
securin has been described nuclear and expressing mainly in the proliferating cell 
layer (Ito et al 2008, Zhang et al 2014). It has been suggested that cytoplasmic 
securin may be associated with Golgi apparatus and have a role in microtubule 
nucleation (Moreno-Mateos et al 2011). 
According to literature, in vertebrates securin is not an essential element in the 
cell cycle as some vertebrate cells lacking the Pttg1 gene can proceed through the 
mitotic process (Mei et al 2001). Also, a Pttg1 null/null mouse model is viable (Mei 
et al 2001, Wang et al 2001) and fertile (Wang et al 2001), although the mice show 
testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia and 
abnormal cytological and chromosomal patterns (Wang et al 2001). The mice are 
also susceptible for the development of diabetes (Wang et al 2003) induced by beta-
cell apoptosis (Chesnokova et al 2009). The bone marrow stem cells from Pttg1 null 
mice show normal differentiation patterns but exhibit lower proliferation, increased 
senescence and increased expression of DNA repair genes (Rubinek et al 2007). 
Transgenic mice overexpressing Pttg1 have slightly increased risk for the 
development of ovarian and fallopian carcinoma and papillary serous 
adenocarcinoma of the pancreas (Fong et al 2012). However, crossbreeding a Pttg1 
overexpressing transgenic mice with Tp53-mutated mice lead to an increased tumour 
development compared to either of the mutations alone suggesting that an additional 
factor is needed for the oncogenic properties of Pttg1 (Fong et al 2012).   
In the early studies, based on in vivo and in vitro experiments, the expression of 
PTTG1 has been suggested to be ER-dependent in pituitary tumours (Heaney et al 
1999). Consequently, overexpression of securin has been detected in ER-responsive 
rat pituitary tumour cell line (Fujimoto et al 1999). Also, exogenous administration 
of ER in mice models has been shown to increase the expression of PTTG1 mRNA 
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and cause hypoplasia and tumorigenesis in pituitary cells (Heaney et al 1999). 
However, the levels of securin expression have not been shown to be controlled by 
ER in vivo (Fujimoto et al 1999). Weather this remains true for breast cancer has not 
been established.  
In addition to its function in the cell cycle, securin also functions as a 
transcriptional factor by directly binding to DNA or by interacting with other 
proteins (Tong and Eigler 2009). By these means, securin has roles in several 
different cell functions. It has been suggested to promote epithelial-mesenchymal 
transition (Xiea and Wangb 2016).  It has been reported to promote angiogenesis by 
upregulating the basic fibroblast growth factor (bFGF) and vascular endothelial 
growth factor (VEGF) (Ishikawa et al 2001, McCabe et al 2002). Moreover, it has 
been suggested to inhibit DNA double-strand break repair by disturbing the Ku 
heterodimer formation (Kim et al 2007). Securin induces p53 expression and 
apoptosis by binding to p53 and interfering with the DNA binding properties of the 
protein (Bernal et al 2002). Other transcriptional targets of securin also include c-
myc (Pei 2001), p21 (Chesnokova et al 2005) and prolactin (Horwitz et al 2003). It 
has also been observed that depleting securin from the cells disturbs normal cell 
migration (Moreno-Mateos et al 2011). 
2.3.1.2 Securin in cancer 
From early on securin was found to be overexpressed in human malignancies 
(Dominguez et al 1998, Zhang et al 1999). After the discovery of the integral 
function of securin in the chromosomal separation, it was speculated that the tumour 
formation might be associated with defects in the sister chromatid separation and, 
thus, the development of aneuploidy (Zou et al 1999). 
PTTG1 overexpression has also been detected in several other types of 
malignancies based on mRNA and protein expressions. Table 3 presents an overview 
of different malignancies where this overexpression has been described in the 
literature.  
Concerning prognostic implications, the overexpression of securin is also 
reported to predict adverse outcome in several malignancies. These prognostic 
implications are outlined in Table 4. 
In literature, the overexpression of securin has been associated with a higher 
stage (Heaney et al 2000, Kim et al 2007, Cui et al 2015), an increased rate of lymph 
node invasion (Rehfeld et al 2006, Ito et al 2008, Yan et al 2009, Zhang et al 2014) 
and an increased rate of tumour recurrence (Solbach et al 2004, Solbach et al 2006, 
Filippella et al 2006, Raverot et al 2010) in several different malignancies.  
In breast cancer, securin has widely been reported as overexpressed both 
immunohistochemically and on gene expression level (Puri et al 2001, Solbach et al 
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2004, Ogbagabriel et al 2005, Yoon et al 2012). This has also been confirmed in our 
own studies, where a cDNA microarray analyses involving 4000 cancer-related 
genes and a comparison of gene expressions between specimen of human breast 
carcinomas and non-cancerous breast tissue revealed PTTG1 as the most 
differentially expressed (Talvinen et al 2008). In further studies, high securin 
expression in cancer cells was associated with aneuploidy and an increased risk of 
breast cancer related death (Talvinen et al 2009, Karra et al 2012). 
Overexpressed securin in breast cancer tissue has been associated with an 
increased risk of lymph node invasion (Solbach et al 2004, Ogbagabriel et al 2005, 
Grizzi et al 2013) and risk of a relapse after treatment (Solbach et al 2004, Ghayad 
et al 2009). It has been suggested that this might be mediated by epithelial-
mesenchymal transition (Yoon et al 2012). Overexpressing securin expression was 
found to lead to the acquisition of invasive properties in breast cancer cell lines 
(Yoon et al 2012). This has raised securin as a potential candidate for treatment, as 
depleting securin from cells decreased cell proliferation in breast cancer cell lines 
(Xiea and Wangb 2016) and suppressed tumour growth (Yoon et al 2012). Also, 
depleting securin from breast cancer cells appears to enhance radiosensitivity and 
induces senescence in the cancer cells, possibly due to disruption of the DNA 
double-strand break repair function of securin (Chen et al 2010). 
 
 
 Table 3  Examples of literature on the overexpression of securin in human malignancies. 
Malignancy Source Material Publication 
Adrenocortical cancer Protein Tissue, cell lines Demeure et al 2013, Romero Arenas et al 2018 
Breast cancer Protein, mRNA Tissue, cell lines Puri et al 2001, Solbach et al 2004, Ogbagabriel et al 2005, Ghayad et al 2009, Yoon et al 2012, Grizzi et al 2013 
Cervical cancer mRNA Tissue Guo et al 2019 
Clear cell renal cancer Protein, mRNA Tissue Wei et al. 2015 
Colorectal cancer mRNA, Protein Tissue, cell lines Heaney et al 2000, Kim et al 2007, Ren and Jin 2017 
Gastric carcinoma Protein, mRNA Tissue Wen et al 2004, Xu et al 2016 
Head and neck squamous cell carcinoma mRNA, Protein Tissue Solbach et al 2006, Heikkinen et al 2016, Ma et al 2018 
Haematological neoplasia Protein Tissue Dominguez et al 1998, Saez et al 2002  
Hepatocellular carcinoma Protein, mRNA Tissue, cell lines Cho-Rok et al 2006, Fujii et al 2006 
Lung cancer Protein, mRNA Tissue, cell lines Rehfeld et al 2006, Kakar 2006 
Malignant gliomas Protein, mRNA Tissue, cell lines Genkai et al 2006, Salehi et al 2013, Cui et al 2015 
Medullary thyroid cancer Protein Tissue Pezzani et al 2019 
Mucoepidermoid carcinoma of the salivary 
gland Protein, mRNA Tissue, cell lines Liu et al 2015 
Multiple myeloma Protein, mRNA Blood, cell lines Chiriva-Internati et al 2008 
Oesophageal squamous cell carcinoma Protein, mRNA Tissue, cell lines Zhou et al 2005, Ito et al 2008, Yan et al 2009, Zhang et al 2014  
Ovarian cancer Protein, mRNA Tissue, cell lines Puri et al 2001, El-Naggar et al 2007, Wang et al 2015 
Pancreatic ductal carcinoma Protein, mRNA Tissue, cell lines Grutzmann, Pilarsky et al 2004, Lin, Chen et al 2013 
Prostate cancer Protein Tissue, cell lines Zhu et al 2006, Cao et al 2012 
Testicular tumours mRNA Tissue Puri et al 2001, Pierconti et al 2015 
Thyroid carcinoma Protein, mRNA Tissue Boelaert et al 2003 
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 Table 4  Summary of prognostic implications of securin in different malignancies reported in the literature. 
Malignancy Method 
Cohort 
(n) 
Over-
expressing 
Fraction 
(%)  
Subcellular 
location in 
IHC Prognostic implications Publication 
Adrenocortical 
carcinoma qRT-PCR 44 NA  
↓ median survival 1.8 years with high expression 
vs. 9.0 years with low expression Demeure et al 2013 
Clear cell renal 
cell carcinoma 
IHC 
qRT-PCR 
192 
44 58.9 
nuclear and 
cytoplasmic 
↓ mean survival 59.72 months with high 
expression vs. 88.28 months with low expression Wei et al 2015 
Colorectal 
carcinoma IHC 118 NA   ↓ Ren and Jin 2017 
Gastric cancer IHC qRT-PCR 
78 
98 74.4 
cytoplasmic 
and nuclear 
↓ mean survival 34.8 months with high expression 
vs. 62.6 months with low expression Xu et al 2016 
Hepatocellular 
carcinoma 
IHC 
qRT-PCR 62 NA  
↓ overall survival rate 58.6 % with high expression 
vs. 82.3 % with low expression Fujii et al 2006 
Laryngeal 
squamous cell 
carcinoma 
IHC 210 88 cytoplasmic and nuclear 
↓ mean survival 28.1 months with high expression 
vs. 38 months with low expression Ma et al 2018 
Non-small cell 
lung carcinoma IHC 91 97.8   
↓ mean survival 306 days with high expression vs. 
463 days with low expression Rehfeld et al 2006 
Oesophageal 
squamous cell 
carcinoma 
IHC 108/113 38.0/60.2  ↓ Zhang et al 2014, Ito et al 2008 
Skin squamous 
cell carcinoma IHC 26 96 
nuclear and 
cytoplasmic expression levels showed no prognostic value Ishitsuka et al 2013 
Small cell lung 
carcinoma IHC 136 64   
↑ mean survival 379 days with high expression vs. 
265 days with low expression Rehfeld et al 2006 
↓ outcome, ↑ outcome NA= not reported IHC= immunohistochemistry qRT-PCR: real-time reverse transcription-PCR 
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2.3.1.3 Subcellular location of securin in cancer 
In the literature, research on the subcellular location of securin in cancer are sparse 
and reports variable observations between in different research settings and in 
different cell lines and tissue types. Based on in vitro experiments, the subcellular 
location of securin varies between several cell lines (Mu et al 2003) and may also 
vary in different phases of the cell cycle (Yu et al 2000, Stratford et al 2005). In 
normal oesophageal squamous epithelium securin has been described nuclear and 
expressed primarily in the proliferating cell layer, whereas the location changed into 
cytoplasmic in squamous cell carcinomas (Ito et al 2008, Zhang et al 2014).  
Expression in both cytoplasm and nucleus has been reported in other malignancies 
e.g. gliomas (Salehi et al 2013) and gastric carcinomas (Xu et al 2016). 
According to some reports, however, securin is expressed as cytoplasmic both in 
benign conditions, such as pituitary adenomas (Tena-Suck et al 2008), as well as in 
malignancy, e.g. gastric (Wen et al 2004), prostatic (Zhu et al 2006) and 
hepatocellular carcinomas.   
In gliomas, the subcellular location of securin has been discussed in association 
with the outcome of the disease, since predominantly nuclear expression has been 
observed in high grade tumours as opposed to cytoplasmic expression in low grade 
gliomas (Salehi et al 2013). 
2.3.2 PTTG1IP 
2.3.2.1 PTTG1IP in normal cells 
Pituitary tumour-transforming gene 1 interacting protein (PTTG1IP), also called 
PTTG1 binding factor (PBF) is a 180 amino acid sequence possessing an N-terminal 
signal peptide, a transmembrane domain, a bipartite nuclear localisation signal and 
a tyrosine-sorting signal (Chien and Pei 2000, Imruetaicharoenchoke et al 2017). 
PTTG1IP has been found to be ubiquitously expressed in a wide variety of human 
tissues such as bone marrow, lymph node, pancreas and thyroid (Chien and Pei 
2000). 
According to present understanding, the subcellular location of PTTG1IP is 
dependent on a nuclear location signal (NLS) in the C terminus and a region 
necessary for interaction with securin (Chien and Pei 2000). The NLS in also 
required for the translocation of PTTG1IP from the cytoplasm to the nucleus (Chien 
and Pei 2000). In normal circumstances, PTTG1IP is located in both the cytoplasm 
and the nucleus. In the absence of the NLS, PTTG1IP is found completely in the 
cytoplasm (Chien and Pei 2000).  
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The full function of PTTG1IP remains still relatively poorly understood. The 
main function of PTTG1IP appears to be the nuclear transport of securin (Chien and 
Pei 2000, Vlotides et al 2007). In thyroid cells PTTG1IP represses iodine uptake by 
transcriptional regulation (Boelaert et al 2007). It has thought to have tumour 
transforming potential (Stratford et al 2005) but this has been questioned as mouse 
models overexpressing PTTG1IP didn’t routinely develop tumours (Read et al 2011) 
2.3.2.2 PTTG1IP and cancer 
Soon after its discovery, PTTG1IP was found to be tumorigenic in mice (Stratford 
et al 2005). More recently, it has been reported to promote cell growth in 
hepatocellular carcinoma cells (Li et al 2013) and increase the invasive properties in 
thyroid and breast cancer cells (Watkins et al 2016). 
In normal breast tissue, PTTG1IP expression is either low or non-existent 
(Watkins et al 2010). It has been suggested that its expression is, at least in part, 
controlled by oestrogen (Watkins et al 2010). PTTG1IP has been found to be 
overexpressed in breast cancer (Watkins et al 2010), where it has also been shown 
to promote invasion (Watkins et al 2010, Watkins et al 2016). In addition to breast 
cancer, PTTG1IP has been found to be overexpressed in two other types of 
malignancies, thyroid (Stratford et al 2005, Read et al 2017) and colorectal 
carcinomas (Read et al 2016). In thyroid carcinomas, PTTG1IP overexpression has 
been associated with unfavourable outcome (Hsueh et al 2013, Read et al 2017) and 
tumour recurrence (Stratford et al 2005).  
The reason for the oncogenic properties of PTTG1IP has eluded research. The 
logical explanation appears to lie in the post-translational modification as among the 
few detected mutations of the PTTG1IP gene, none are known to have oncogenic 
properties (Imruetaicharoenchoke et al 2017). Another promising explanation might 
involve the association between PTTG1IP and P53 reported in thyroid and colorectal 
carcinomas (Read et al 2014, Read et al 2016). 
2.3.2.3 PTTG1IP subcellular location in cancer 
Based on in vitro experiments, PTTG1IP in cancer cells is mainly found in the 
cytoplasm, co-localized with securin (Stratford et al 2005). Based on evidence from 
thyroid cancer, it has been suggested that PTTG1IP is expressed in both the nucleus 
and the cytoplasm (Stratford et al 2005). Also, in colorectal carcinoma mainly 
cytoplasmic expression has been reported (Read et al 2016). However, some 
researchers have also reported on primarily membranous expression of PTTG1IP 
(Hsueh et al 2013). 
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2.3.3 Separase 
2.3.3.1 Separase in normal cells 
Separase (also extra spindle poles-like 1, ESPL1) is one of the main proteins 
responsible for maintaining the chromosomal integrity of the cell throughout mitosis. 
The ESPL1 gene is located in the 12q13.13 chromosomal region and encodes the 
protein separase, which, in humans, is expressed in several isoforms. Separase is a 
cysteine protease and an endopeptidase with the main function to monitor 
chromosomal fidelity at metaphase-anaphase transition (Nasmyth and Haering 
2009).  
As the activation of separase in late metaphase triggers the cleavage and 
inactivation of the Scc1/Rad21 subunit of cohesin and the progression to anaphase, 
it must be accurately controlled to prevent a premature onset of anaphase. To 
maintain this control, there are several different mechanisms, independent of each 
other. The best-known regulator of separase is securin, as outlined in Chapter 2.3.3. 
Binding to securin inhibits the activity of separase during most of the cell cycle but 
when securin is degraded by the APC/C at the onset of anaphase, separase is 
activated and released (Shirayama et al 1999, Uhlmann 2003). Separase may also be 
inactivated via phosphorylation by cyclin B‐dependent Cdk1 (Ciosk et al 1998, Gorr 
et al 2005). There is also research suggesting a still relatively poorly understood 
autocleavage mechanism may partake in this tight regulatory process (Zou et al 2002, 
Waizenegger et al 2002). However, it has been suggested that a low level of separase 
activity is maintained during the whole cell cycle (Kumar 2017) and that both securin 
and Cdk1 also have separase activating properties in addition to their inactivating 
functions (Hellmuth et al 2015). The activated separase at anaphase cleaves the 
cohesin binding the sister chromatids together, but only at the centromeres 
(Waizenegger et al 2000).  
At interphase, separase is located in the cytoplasm. The relatively large size of 
the protein and the lack of nuclear localization signal prevent the transition through 
the nuclear membrane. In addition, separase contains a nuclear export signal, further 
increasing the restriction to the cytoplasm. Thus, only the destruction of the nuclear 
membrane during the prometaphase allows the separase to gain access to the nuclear 
proteins, i.e. cohesin (Zhang and Pati 2017).  
In addition to functioning at the metaphase-anaphase transition, it has been 
suggested that separase participates in the cell cycle in spindle assembly, centrosome 
cycle, DNA damage repair and membrane trafficking (Zhang and Pati 2017, 
Hellmuth et al 2018). Based on experiments resulting in siRNA-induced depletion 
of ESPL1, separase has also been suggested with a conserved role in telomere 
protection (Cipressa et al 2016). Based on studies in healthy individuals, genetic 
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variations in ESPL1 have been suggested to induce formation of chromosomal 
aberrations in the diving cell (Försti et al 2016). Abnormal function of separase 
halting the continuation of the cell cycle into anaphase has been reported to 
predispose the cell for premature separation of chromatids, lagging chromosomes 
and anaphase bridges, known indicators of chromosomal instability and aneuploidy 
(Zhang and Pati 2017). Consequently, ESPL1 has been associated with chromosomal 
instability (Fridlyand et al 2006, Ignacio Pérez de Castro et al 2007), single 
nucleotide pleomorphism (Brendle et al 2009) and included in a gene expression 
signature of aneuploidy in several human malignancies (Carter et al 2006). 
2.3.3.2 Separase in cancer 
Analyses of gene expression and comparative genomic hybridization have suggested 
the association of separase overexpression with loss of tumour suppressor genes P53 
and Rb (Pati 2008). In addition, response elements for oestrogen and progesterone 
have been detected in the ESPL1 promoter region and separase overexpression has 
been associated with mammary tumorigenesis (Zhang et al 2008, Mukherjee et al 
2014). More recently, Zhang and co-workers have identified Sepin-1, an inhibitor of 
separase, which has been shown to inhibit the growth of ER-positive breast cancer 
cell lines and breast cancer xenografts in mice and, in most cases, reflect the 
expression levels of separase in both cancer cell lines and in tumours (Zhang et al 
2014). In summary, separase, when overexpressed acts as an oncogene with 
important roles in the malignant progression, and inhibition of separase constitutes 
a promising strategy for treating aneuploid cancers.  
Previously, separase has been shown overexpressed in a wide range of human 
malignancies, including carcinomas of breast, prostate, and bone (Meyer et al 2009, 
Zhang and Pati 2017) and gliomas (Mukherjee et al 2014). Based on gene and 
miRNA expressions, separase has been associated with the pathogenesis and 
prognosis of endometrial and gastric carcinomas. Even though separase is often 
overexpressed on protein level in malignancies, the mutation frequency is relatively 
low (Zhang and Pati 2017)  
In breast cancer, more than half of the tumours have been reported to be 
significantly overexpressed by separase as compared to the matched normal tissues 
(Zhang et al 2008, Zhang and Pati 2017). Particularly, the role of separase has been 
demonstrated in ER-dependent breast carcinomas based on experiments where 
carcinomas corresponding to luminal B tumours were developed in transgenic mice 
overexpressing the Espl1 gene (Mukherjee et al 2014). The role of ESPL1 as a driver 
oncogene in luminal B breast carcinomas has been supported based on profiling 
miRNA overexpression (Cornen et al 2014). Associations with clinic-pathological 
features of breast cancer have shown that separase overexpression in an independent 
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predictor of aggressive course of disease and poor survival in breast carcinomas, 
particularly in the luminal B subtype (Mukherjee et al 2014, Gurvits et al 2017). 
2.3.3.3 The subcellular location of separase in cancer 
Previous literature concerning the subcellular location of separase in cancer is sparse 
and partly contradictory. Also, it is not completely understood how overexpression 
and subcellular location of separase are interrelated or contribute to the formation 
and the clinical behaviour of the tumour.  
The major part of the literature suggests that in tumour cells high separase 
expression is constitutively nuclear regardless of the proliferative status of the cells 
(Meyer et al 2009). On the other hand, separase has been described as a cytoplasmic 
protein, which is segregated from the nucleus during interphase by the nuclear 
envelope (Sun et al 2006). In addition, other expression patterns have been described 
and speculated to reflect the specific roles of separase in oncogenesis. Previously the 
role of nuclear localization of separase has been elaborated in glioblastomas, where 
separase was observed in both the nucleus and the cytoplasm, while nuclear 
expression indicated a higher incidence of relapse and disease mortality (Mukherjee 
et al 2014). Instead, aggressive clinicopathological features and reduced survival has 
been associated with cytoplasmic localization of separase in breast carcinomas, 
whereas non-neoplastic breast luminal epithelium showed nuclear expression of 
separase.  
In previous literature, several explanations for the subcellular location of 
separase has been speculated, the most obvious being that the intensive 
overexpression of separase may overwhelm the normal mechanism of separase 
expression, the export of separase from the nucleus of proliferating tumour cells may 
be hampered of nuclear retention of separase results in premature removal of the 
sister chromatids (Nagao et al 2004, McAleenan et al 2013).  
2.3.4 SA2 
2.3.4.1 SA2 in normal cells 
Cohesin is a multiunit protein complex responsible for the cohesion of the sister 
chromatids during metaphase assuring their proper alignment as presented 
previously in Chapter 2.3.3. In somatic cells, the human cohesin consists of four 
different subunits SMC1, SMC2, RAD21 and either SA1/STAG1 or SA2/STAG2 
subunit. One cohesin complex is associated with either a SA1 or SA2 subunit, so that 
SA1 subunit is more likely associated with centromere and chromosome arms while 
a cohesin complex containing a SA2 subunit is mainly located at the telomeres 
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(Canudas and Smith 2009). These four proteins form a ring-like structure encasing 
the sister chromatids immediately after cytokinesis (Brooker and Berkowitz 2014). 
At interphase SA2 is located in the nucleus (Losada et al 1998) where is has been 
transported from the cytoplasm. This transportation is facilitated by a nuclear 
localization signal at the C-terminal fragment of the protein (Tarnowski et al 2015). 
At prophase, most of the cohesin complexes at chromosome arms are disassociated 
by phosphorylation of the SA subunits (Hauf et al 2005). At the centromeres cohesin 
is removed more slowly as the SA2 subunit protected from the hyperphosphorylation 
by shugoshins (McGuinness et al 2005). At the metaphase-anaphase transition the 
rest of the complexes are actively removed by separase activated by the APC/C 
cleaving the RAD21 subunit (Morales and Losada 2018), independent of the 
phosphorylation status (Hauf et al 2005). It is known that SA2 is dependent on 
RAD21 but not the other way around and depleting RAD21 from the cells 
destabilizes the SA2 (Vass et al 2003). Depleting SA2 from a cell does not lead to 
premature separation of sister chromatids whereas depleting RAD21 does (Vass et 
al 2003).  
In addition to the role in sister chromatid cohesion, cohesin also functions in 
DNA damage repair at the S/G2 phase and the SA2 subunit – not SA1 – is 
responsible for the recruiting cohesin to the damage sites (Kong et al 2014). In DNA 
repair, some reports indicate that depleting SA2 from a cell increased the amount of 
SA1 in the cell (Kong et al 2014). This observation suggests a possible compensatory 
mechanism between SA1 and SA2 although this finding could not be confirmed by 
others (Solomon et al 2011). It has also been suggested that SA2 might also have a 
function as a transcriptional co-activator (Lara-Pezzi et al 2004).  
In contrast to most cell cycle proteins, SA2 immunohistochemical expression 
can be found in most non-neoplastic tissues (Solomon et al 2011), including stromal 
fibroblasts. 
2.3.4.2 SA2 in cancer 
The loss of SA2 expression has been reported in several cancer cell lines such as 
glioblastoma (Solomon et al 2011), Ewing sarcoma (Solomon et al 2011, Tirode et 
al 2014, Crompton et al 2014, Brohl et al 2014) and malignant melanoma (Solomon 
et al 2011). Loss of expression has also been reported in a minority urothelial and 
pancreatic adenocarcinoma (Solomon et al 2013, Evers et al 2014) and the majority 
of gastric, colorectal and prostate carcinomas (Kim et al 2012). In urothelial 
carcinoma, the loss of expression was associated with a truncating mutation 
(Solomon et al 2013). 
In prognostic evaluations, the loss of SA2 expression has been associated with 
increased disease mortality in invasive urothelial carcinomas (Solomon et al 2013). 
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Instead, in pancreatic carcinomas SA2 expression has been associated with higher 
survival rates, whereas the loss of expression predicted positive response to adjuvant 
chemotherapy (Evers et al 2014). 
In literature, several somatic genetic mutations are proposed leading to the loss 
of SA2 expression in cancer cells (Solomon et al 2011, Taylor et al 2014). In some 
studies, these mutations have been associated with chromosomal instability and 
aneuploidy (Solomon et al 2011) while most studies have not confirmed this finding 
(Balbas-Martinez et al 2013). Interestingly, in glioblastoma cells correcting these 
mutations was observed to lead to regained expression of SA2 and rescue of 
chromosomal stability (Solomon et al 2011) but this result could not be repeated in 
urothelial cells (Solomon et al 2013). 
At present no literature on the expression on the prognostic role of SA2 in breast 
cancer is available. However, the SA2 coding gene STAG2 is included in some gene 
sets proposed as possible prognostic markers in breast cancer (Chang et al 2016). 
2.3.4.3 The subcellular location of SA2 in cancer 
As the amount of data on the expression of SA2 in malignancy is limited, the number 
of reports on the subcellular location of SA2 is also low. However, in the available 
publications, the expression of SA2 is reported to be nuclear as evidenced in Ewing 
sarcoma (Brohl et al 2014), urothelial carcinoma (Solomon et al 2013) and pancreatic 
adenocarcinoma (Evers et al 2014). The expression has also been found to be nuclear 
in the normal tissues such as the fibroblasts surrounding the tumour cells (Solomon 
et al 2013, Brohl et al 2014) 
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3 Aims 
This study concentrates on expressions of specific regulatory proteins of the 
metaphase-anaphase transition of the cell division, and their potential value in 
predicting the prognosis of breast carcinoma patients. 
 
The specific aims of this theses are: 
1. To demonstrate the protein expressions of selected regulators of meta-phase-
anaphase transition, Securin, PTTG1IP, separase and SA2 in breast cancer (I–
IV) 
2. To demonstrate the prognostic impact of securin, PTTG1IP, separase and SA2 
in breast cancer (I–IV) 
3. To evaluate the relevance of securin, PTTG1IP, separase and SA2 in relation 
to clinical prognosticators in breast cancer (I–IV) 
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4 Materials and Methods 
4.1 Patient and tissue materials 
4.1.1 Patients (I–IV) 
The material consists of a total of 1135 women diagnosed and treated for invasive 
breast carcinoma (Table 5). The first cohort (n=781) was treated in Central Hospital 
of Central Finland, Jyväskylä, Finland, in 1987–1997, representing the era of 
national breast cancer screening. The second cohort was collected in association with 
Auria Biobank, Turku, Finland, and consisted of 354 women with invasive breast 
carcinoma treated between the years 2005 and 2015 in Turku University Hospital, 
Turku, Finland. The patient cases in both cohorts were non-consecutive.  
All patients were treated with surgical resection or a mastectomy with sentinel 
lymph node biopsy and/or axillary lymph node evacuation when necessary. After 
surgery the patients received radiation therapy or adjuvant treatment with anti-
estrogenic or cytostatic drugs based on the international guidelines for breast cancer 
treatment at the time of the diagnosis. All patients who had received neoadjuvant 
treatment were excluded from the material. Complete clinical data and follow-up 
data was collected from pathology reports and patient files. The patients were 
allocated into subgroups of the intrinsic classification according to the 
recommendations of the of the 12th St Gallen International Breast Cancer 
Conference Expert Panel (Goldhirsch et al 2011).  
The maximum follow-up period in the material was 22 years and 6 months (mean 
10 years). Causes of death were obtained from autopsy reports, death certificates and 
from the Finnish Cancer Registry. 
  
Table 5 Summary of clinico-pathological parameters of the study I–IV). 
 Studies 
 I II III IV 
Total amount of patients 445 447 401 96 781 354 
Mean follow-up time (range) (years) 10.0 (0.02-20.3) 10.0 (0.02-20.3) 10.0 (0.02-22.5) 5.1 (0.08-11.7) 12.4 (0.02-22.7) 9.4 (0.08-17.8) 
Mean age at dg (range) (years) 61 (28-95) 58 (39-78) 56 (39-78) 62 (32-93) 61 (28-95) 60 (39-78) 
Axillary lymph node positive n (%) 222 (50) 228 (51) 187 (46) 33 (35) 351 (45) 99 (29) 
Mean tumour size (range) (cm) 2.4 (0.2-10.0) 2.4 (0.2-10.0) 2.4 (0.2-10.0) 2.7 (0.8-18.0) 2.3 (0.2-16.0) 2.4 (0.2-18.0) 
Breast cancer deaths n (%) 142 (32) 152 (32) 141 (35) 21 (22) 234 (30) 57 (22) 
Histological type n (%)       
Infiltrating ductal  356 (80) 358 (80) 332 (82) 96 (100) 589 (75) 354 (100) 
Special type 89 (20) 89 (20) 72 (18) 0 192 (25) 0 
Intrinsic subtype n (%)       
Luminal 343 (77) 154 (67) 281 (69) 0 528 (67) 208 (59) 
Her2-amplified 31 (7) 37 (16) 51 (15) 0 145 (19) 0 
Triple-negative 71 (16) 39 (17) 47 (17) 96 (100) 108 (14) 146 (41) 
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4.1.2 Tissue materials (I–IV) 
The breast carcinoma specimen in were prepared according to the standard histology 
practice i.e. fixed in buffered formalin (pH 7.0) and embedded in paraffin. Both 
materials were collected in tissue microarrays (TMAs). This was performed first, by 
identifying in H&E staining two representative cancer cell areas. Next, the paraffin 
blocks were punched in these areas to obtain two tissue cores from each tumour. The 
diameter of the tissue cores was 0.6 mm – 1.5 mm.  
4.1.3 Ethical considerations 
The research was approved by the Regional Ethics Review Boards of Turku 
University Hospital and Auria Biobank, Turku Finland, Central Hospital of Central 
Finland, Jyväskylä, Finland and Finnish Cancer Registry, Cancer Society of Finland, 
Helsinki, Finland (permit numbers 6/2002, AB15-9859 and TK-53-716-16). All 
research procedures involving human participants were performed in accordance 
with the ethical standards of the World Medical Associations code of ethics 
(https://www.wma.net/policies-post/wma-international-code-of-medical-ethics/) 
and the 1964 Helsinki declaration and its later amendments (https://www.wma.net/ 
policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-
involving-human-subjects/). 
4.2 Histological methods 
4.2.1 Immunohistochemistry (IHC) (I–IV) 
The primary antibodies and their respective procedures of antigen retrieval and 
detection for identification of securin, PTTG1IP, separase and SA2 are summarized 
in Table 6.  
Table 6  Details of IHC for securin, PTTG1IP, separase, SA2, ER, PR, HER2 and Ki-67. 
  Origin Clone Source Dilution 
Antigen 
retrieval Incubation 
Securin mouse DCS-280 Abcam ab3305 1:100 Microwave 1h RT 
PTTG1IP rabbit polyclonal Abcam ab128040 1:500 on platform 20min 37° 
Separase mouse 6H6 
Novus biologicals 
H00009700-M01 1:300 Microwave 1h RT 
SA2 mouse 3C6 Abcam ab4463 1:500 sCC1 32min 37° 
ER rabbit SP1 Roche RTU sCC1 24min 37° 
PR rabbit 1E2 Roche RTU sCC1 32min 37° 
HER2 rabbit 4B5 Roche RTU sCC1 24min 37° 
Ki-67 rabbit 30-9 Roche RTU sCC1 12min 37° 
sCC1= standard Cell Conditioning 1 RTU=ready to use RT= room temperature 
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In short, IHC to detect securin and separase applied Lab Vision Autostainer 480 
(Thermo-Fisher Scientific, Fremont, CA, USA) and detection using 
PowerVision+polymer kit, according to the manufacturer’s protocol 
(DPVB+110HRP Immunovision Technologies, Vision Biosystems, Norwell, MA, 
USA), with diaminobenzidine as chromogen. SA2 applied Benchmark XT (Roche 
Diagnostics/Ventana Medical Systems, Tucson, AZ, USA) and detection with 
ultraView Universal DAB Detection Kit (Roche Diagnostics/Ventana Medical 
Systems, Tucson, AZ, USA). PTTG1IP-IHC applied Discovery XT (Roche 
Diagnostics /Ventana Medical Systems, Tucson, AZ, USA) with OmniMap HRP and 
Chromomap DAB Kit (Roche Diagnostics /Ventana Medical Systems, Tucson, AZ, 
USA) for detection.  
4.2.1.1 Interpretation of IHC (I–IV) 
The IHC expressions of securin, PTTG1IP, separase and SA2 were registered as the 
percentage of positive cells analysed from sets of 100 tumour cells. In minimum 100 
and in maximum three sets of 100 cells were evaluated. For securin and separase, also 
the subcellular location of staining was evaluated and registered as predominantly 
nuclear or cytoplasmic, or the combination of both (III–IV). Only tissue cores showing 
more than 100 cells were included in the studies. Control materials comprised whole 
tissue sections obtained from surgical reductions of normal breast and TMA cores 
representing benign breast tissue outside the tumour areas. 
4.2.2 Detection of clinicopathological prognostic parameters 
(I–IV) 
The primary antibodies and applied IHC procedures used in the antigen retrieval and 
detection ER, PR, HER2 and Ki-67 are summarized in Table 6. The IHC for 
detecting ER, PR, Ki-67 and HER2 was performed on Benchmark XT (Roche 
Diagnostics/Ventana Medical Systems, Tucson, AZ, USA) and the signals were 
detected ultraView Universal DAB Detection Kit (Roche Diagnostics/Ventana 
Medical Systems, Tucson, AZ, USA). The interpretation of ER, PR and Ki-67 IHC 
was performed according to generally accepted international guidelines (Hammond 
et al 2010). On the bases of HER2-ICH (intensity score 2+ or 3+) cases were selected 
for gene amplification verification by in situ hybridization (ISH) (Wolff et al 2013). 
HER2/Chr17 double ISH were performed using Benchmark XT (Roche 
Diagnostics/ Ventana Medical Systems, Tucson, AZ, USA), the HER2 DNA and the 
Inform Chromosome 17 probe set, and the ultraView SISH detection kit to detect 
HER2 (Roche/ Ventana) and the ultraView Alkaline Phosphatase Red ISH Detection 
Kit to detect Chr17 (Roche/Ventana).  
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4.3 Statistical analysis (I–IV) 
To begin with, the patients were categorized into subgroups exhibiting low versus 
high expression of the studied proteins. This was performed by selecting cutpoints 
based on, first, the observations of the IHC interpretations and, secondly, on 
statistical analyses involving the mean and median values of each parameter. Finally, 
the optimal cutpoint for each protein was verified based on univariate analyses where 
the chosen cutpoint produced the strongest prognostic value between breast cancer-
specific survival vs. death in our material. Consequently, the cutpoint for securin was 
set at 10% immunopositive cells (< 10% vs. ≥ 10%) in agreement with previous 
literature (Talvinen et al 2008). The subcellular location of securin was categorized 
based on observed cytoplasmic expression of securin in the minority (< 50%) vs. the 
majority (≥ 50%) of the cells. Among the cases exhibiting the extreme ends of these 
patterns, a further separation was performed for the cases where < 10% vs.  ≥ 90% 
of securin was observed in the cytoplasmic compartment of the cancer cell. For 
PTTG1IP the categorization between low vs. high expression was done at 10% of 
immunopositive cancer cells (< 10% vs. ≥ 10%). The extent of nuclear separase 
immunoexpression was registered as fraction of positive cancer cells (< 1% vs. ≥ 
1%). For SA2, the categorization between low vs. high expression was done at 5% 
of immunopositive cancer cells (< 5% vs. ≥ 5%).   
Intra-class correlation coefficients were used in reproducibility analyses 
reflecting the inter- and intra-observer consistencies between different observers and 
settings. In prognostic analyses, Kaplan-Meier estimates were performed to 
demonstrate the cumulative percentages of breast cancer specific mortality, and 
Cox’s proportional hazard models were used to assess associations between protein 
expressions and disease outcome. Cox regression analysis was used to assess the 
prognostic associations adjusted for the established prognostic features, tumour size, 
axillary lymph node status, histological and intrinsic cancer type and histological 
grade.  
Relations between the studied proteins and the established clinical 
prognosticators were qualified as hazard ratios (HRs) with 95% confidence intervals 
(CIs). Associations between the expressions of the proteins studied and the 
established clinical prognosticators were analysed by Fisher’s exact and Wilcoxon 
rank sum tests, and the results were quantified as odd ratios (ORs) with 95% 
confidence intervals. P-values <0.05 were considered statistically significant. The 
validity of the proportional hazards assumptions was assessed both visually and 
numerically, and no marked deviation from assumptions was observed.  
The computations were performed with SAS for Windows, Version 9.3 (I-III) 
and 9.4 (IV) (SAS Institute, Cary, NC, USA) Kaplan-Meier survival plots were 
generated using R 2.15.0. 
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5 Results 
5.1 Expression of securin, PTTG1IP, separase and 
SA2 in breast cancer 
5.1.1 Expression of securin (II) 
In normal breast tissue, immunoreaction for securin was observed only in single cells 
(< 1%) of the luminal epithelium (Figure 5) (II). The expression was solely or 
primarily nuclear while cytoplasmic expression alone was not detected in benign 
breast specimen (II). 
In breast carcinomas, securin immunoexpression was observed in average in 
8.3% of malignant cells (II). In material allocated to intrinsic subgroups, a 
significantly higher fraction of immunopositivity was observed for TNBCs than for 
HER2-amplified or luminal carcinomas (p<0.0001) (Figure 4 in II). 
Concerning the subcellular location of securin, we found that 38% of the cases 
showed cytoplasmic expression in the majority of the cancer cells. Most of these 
latter cases (64%) represented histological grade 3 tumours. Among the remaining 
cases in which cytoplasmic securin expression was observed in the minority of the 
cancer cells, histological grade 1 and 2 were overrepresented (38% and 51% of the 
cases, respectively) (II). Correspondingly, the average fraction of cytoplasmic 
securin positive cells varied according to the intrinsic subtypes from high in TNBCs 
to low in luminal carcinomas. In Cox regression analysis, even slight cytoplasmic 
expression (in <10% of securin positive cells) indicated increased probability for 
TNBC (OR 4.0, p=0.002, CI 1.6–9.5 %) (II). 
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Figure 5 Photomicrographs showing immunoexpressions of securin, PTTG1IP, separase and 
SA2 in normal breast epithelium and in breast carcinomas representing low and high 
histological grade. 
5.1.2 Expression of PTTG1IP (III) 
In normal breast epithelium, single cells showed cytoplasmic PTTG1IP expression 
(Fig. 5) (III).  
In breast carcinomas, PTTG1IP was observed as diffuse cytoplasmic staining 
expressed in an average of 74.3 % of the cases (III). The majority (56%) of 
carcinomas showed positivity in more than 10% of cancer cells (II). In material 
allocated into intrinsic subgroups, PTTG1IP was inversely associated with 
Results 
 45 
aggressivity of the tumour as compared between luminal carcinomas vs. TNBCs 
(p<0.001) and between low vs high histological grade (p<0.001). 
An association between expressions of securin and PTTG1IP was observed both 
morphologically and statistically among all carcinomas and in material divided into 
intrinsic subtypes. In statistical analyses, loss of PTTG1IP was related to the 
cytoplasmic location of securin (p<0.0001) (III). Also, morphologically, cancer cells 
exhibiting PTTG1IP-positivity showed nuclear securin expression while, in the 
absence of PTTG1IP cytoplasmic securin was observed (Figure 2 in III).  
5.1.3 Expression of separase (IV) 
In the normal breast, diffuse separase expression was observed in the nucleus and 
cytoplasm of epithelial cells, occasionally, also in the surrounding stromal cells (Fig. 
5). 
In breast carcinomas, separase immunopositivity was observed as nuclear 
positivity in mitotic cells (Fig. 5). Positivity for separase was observed in 31% of all 
breast carcinomas (I). 
5.1.4 Expression of SA2 (I) 
In normal breast specimen, SA2 was observed as a strong and uniform nuclear and 
cytoplasmic expression in both breast epithelium and stromal fibroblasts (Fig. 5).  
In malignant cells, the pattern of SA2 expression was similar to benign breast 
epithelium and present in approximately one third (28%) of all breast carcinomas (I). 
Even in carcinomas with loss of SA2 expression in the malignant cells, positivity in 
stromal fibroblasts was still visible (I). An association between the reduced SA2 
immunoexpression in cancer cells was observed in subgroups of different 
histological grades (p=0.005) and nodal status (p=0.03) (I). All morphologically 
identifiable mitotic figures were negative for SA2 in benign epithelium and stromal 
cells as well as in carcinoma cells (I). 
5.2 Prognostic associations of securin, PTTG1IP, 
separase and SA2 in breast cancer 
5.2.1 Prognostic associations of securin (I–IV) 
Breast cancer survival was significantly associated with the fraction of securin 
expressing cells and with the subcellular location of the expression (Table 7) (II).  
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Table 7 Summary of prognostic impacts of securin, PTTG1IP, separase and SA2 as evaluated 
in univariate and multivariate analyses including nodal status, tumour size and 
histological grade as clinical features. 
    univariate multivariate 
    HR P CI HR p CI 
Securin, nuclear (II) 2.7 <0.0001 1.6-2.7 2.4 <0.0001 1.5-3.8 
Securin, cytoplasmic (II) 1.6 0.003 1.1-2.4  ns.  
PTTG1IP (III) 1.5 0.02 0.9-2.7  ns.   
Separase (IV) 2.0 <0.0004 1.4-3.0 5.7* 0.002  1.9-17.2 
SA2 (I) 1.6 0.02 1.1.2.5  ns.  
*luminal carcinomas only 
High fraction of securin expressed cells (≥ 10% of cancer cells) indicated significant 
increase of breast cancer mortality in univariate analyses (p<0.001) (Table 8) (II). In 
multivariate analyses involving nodal status, tumour size and histological grade, 
securin showed independent prognostic impact (HR 2.4, p<0.0001, CI 1.5–3.8) (Table 
3 in II). The intensity of securin immunoexpression did not have any statistical 
association with survival or with the clinical prognosticators of breast cancer (I). 
Subcellular localization of securin was also found to predict outcome of breast 
cancer. Risk of disease-specific mortality was increased 1.6-fold among patients 
exhibiting securin expression predominantly (in ≥ 90% of the securin-expressing 
cancer cells) in the cytoplasm of the cancer cells (p=0.003, CI 1.1–2.4) (Figure 7) (II). 
When comparing the extreme ends of cytoplasmic securin expression (< 10% vs. ≥ 
90% of the carcinoma cells showing cytoplasmic expression), the majority of the 
patients (75% quartile) with sparse cytoplasmic expression were alive after 11.2 years 
after diagnosis. Instead, among tumours with high expression of cytoplasmic securin, 
the patients’ expected survival time was only 4.2 years after diagnosis (I). Cytoplasmic 
securin expression was also found to be associated with breast cancer mortality among 
in the patient subgroups divided according to nodal status, tumour size and histological 
and intrinsic classification but these associations were not statistically significant (I).  
In multivariate analyses, the cytoplasmic expression of securin analysed together 
with nodal status, tumour size, histological grade and intrinsic classification failed 
to show statistical significance (p=0.06) (I).  
5.2.2 Prognostic associations of PTTG1IP (III) 
In univariate analyses, lack of PTTG1IP immunoexpression predicted a 1.5-fold 
increased risk of breast cancer death (p=0.02) (Table 7) (III). Survival curves of 
Kaplan-Meier analysis (Figure 6) revealed that in the majority (75%) of the patients 
with PTTG1IP-expressing carcinomas survived 11.4 years while the majority of 
patients with carcinomas lacking PTTG1IP expression were alive only 6.4 years after 
diagnosis (III).  
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Figure 6  Kaplan-Meier curves representing breast cancer-specific survival determined according 
to the immunoexpression of securin, PTTG1IP, separase and SA2 alone (A-D) and in 
combinations (E-H based on a maximum of 22-year follow-up.   
When evaluating the combined prognostic impact of PTTG1IP and securin, the 
subgroup of patients with tumours showing a low PTTG1IP expression and high 
securin expression was associated with a 2.3-fold (p<0.001, CI 1.6-5.4) increased 
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risk of breast cancer mortality as compared with patients exhibiting the combination 
of low securin and high PTTG1IP expression in their tumours (III). 
In the multivariate setting, PTTG1IP expression did not show prognostic value 
in the whole material or patient subsets (III).  
5.2.3 Prognostic associations of separase (IV) 
In univariate analyses, high nuclear separase immunoexpression predicted doubled 
risk of breast cancer death (p<0.0004, CI 1.4–3.0). When tested in combination, high 
expression of separase and securin indicated significantly increased risk of breast 
cancer mortality (p<0.0001) (IV). Detailed quartile estimations of Kaplan–Meier 
analysis (Fig. 6) for individual patients suggested that the majority (75%) of patients 
with favourable combination of proteins (low expression) were alive 18.4 years after 
diagnosis, while unfavourable pattern of the proteins (high expression) suggested 
that one quarter (25 %) of the patients were dead of breast cancer after 2.5 years of 
diagnosis (IV). High separase also predicted breast cancer survival among luminal 
carcinomas (HR 5.7, p=0.002, CI 1.9–17.2) but not among TNBCs (IV). 
5.2.4 Prognostic associations of SA2 (I) 
In univariate analyses, immunoexpression of SA2 was significantly associated with 
breast cancer-specific mortality (p=0.02) (Table 8) (I). The lack of SA2 expression 
was associated with a 1.6-fold risk of breast cancer death (CI 1.1–2.5) (I). 
Concluding from Kaplan-Meier curves of survival analyses, the majority (75% 
quartile) of the patients with low SA2 expression were alive 6.0 years after the 
diagnosis, whereas the majority of the patients with high SA2 expression survived 
17.6 years after the diagnosis (Fig. 7) (I). In addition, SA2 immunoexpression was 
significantly associated with metastatic disease of the axilla (p=0.04) and lack of 
HER2 amplification (p=0.03) (I).  
The combined prognostic impact of SA2 and securin was not statistically 
significant in the material (I). 
In multivariate analysis involving SA2 with the established clinical 
prognosticators of breast cancer, SA2 did now show independent prognostic value (I). 
5.2.5 The clinical relevance of securin, PTTG1IP, separase 
and SA2 in relation to the clinical parameters of breast 
cancer (IV) 
In multivariate analyses, only securin and separase showed independent prognostic 
value when evaluated in combination with the established prognosticators of breast 
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cancer, axillary lymph node status, tumour size, histological grade and intrinsic 
classification (Table 8) (IV). Among all subtypes of carcinomas (n=781), the risk of 
breast cancer mortality was almost equally severe for patients with tumours 
exhibiting high securin immunoexpression and axillary lymph node metastasis (HR 
2.5 and 2.6, respectively, p<0.001) (IV). In the current research, the independent 
prognostic value of separase was evaluated only among luminal breast carcinomas 
(HR 5.7, p=0.002, CI 1.9–17.2). Instead, PTTG1IP and SA2 did not show 
independent prognostic value in the material (IV). 
Finally, the prognostic value of securin-related regulators of the metaphase-
anaphase transition of the cell cycle were designed into multi-parametric models. In 
the development of the models, securin, separase, CDC20, PTTG1IP, SA2, Cdk1, 
and Cyclin B1 were involved and compared to the prognostic potential of the 
established prognosticators of breast cancer, axillary lymph node status, tumour size, 
histological grade, intrinsic classification, immunopositivity for ER, PR and Ki-67, 
and HER2 amplification status (IV).  
Table 8  Summary of multivariate analyses involving securin, PTTG1IP, separase and SA2 and 
the established prognosticators of breast cancer, axillary nodal status, tumour size, 
histological grade and intrinsic classification*. Also, results of the combination of securin, 
separase and cdk1 (model 1), and securin, separase and nodal status (model 2) are 
presented. Only statistically significant prognostic associations are shown. Results are 
presented for all breast carcinomas and for subgroups of axillary lymph node positive 
(N+) and negative (N-) patients, and luminal carcinomas.  
Paper Patients (n) Features HR p-value CI 
II: All (447) securin 2.4 <0.001 1.5-3.8 
  nodal status 2.8 <0.001 1.8-4.3 
  tumour size 1.2 0.003 1.1-1.4       
IV: All (781) model 1 8.4 <0.0001 3.4-20.7 
  nodal status 4.3 <0.0001 2.6-7.0       
 N+ (350) model 1 6.5 0.0003 2.3-17.9       
 N- (431) model 1 19.5 0.006 2.3-163.8       
 Luminal (208) securin 1.1 0.02 1.0-1.2 
  separase 5.7 0.002 1.9-17.2 
  nodal status 4.9 0.003 1.7-13.7 
    model 2 6.2 0.0006 3.2-82.6 
The analysis has been performed on material divided into subgroups with favourable vs 
unfavourable outcome as follows: securin < 10% vs ≥ 10% of immunopositive cancer cells, nuclear 
separase < 1% vs ≥ 1% of immunopositive cancer cells, and tumour size < 2cm vs ≥ 2cm in diameter 
Among all subtypes of breast carcinomas (n=781), the optimal model for detecting 
favourable outcome of disease involved securin, separase and cdk1. The 
unfavourable combination, i.e. high expression of all three markers (≥ 10% of cancer 
cells), separase (≥ 1% of cancer cells) and cdk1 (≥ 10% of cancer cells) indicated 
significantly increased risk of breast cancer death (HR 8.4, p<0.0001, CI3.4–20.7) 
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(IV). The Kaplan-Meier curves (Fig. 6) demonstrate the survival difference among 
all patients and N+ and N- patients (Fig 6). The survival curves indicate that the 
majority (>75%) of patients with tumours resulting in favourable combination of the 
model were alive 18.4 years after primary diagnosis while the unfavourable 
combination indicated 2.5-year survival for the remaining patients (25%) of the 
material (IV). Among the subgroup of N- patients, no cancer-related deaths were 
observed among patients exhibiting favourable combination of the model (IV). 
Instead, the unfavourable combination suggested cancer mortality for every fourth 
patient within 5.3 years from diagnosis (IV). Correspondingly, the majority of N+ 
patients with favourable and unfavourable combination were alive after 17.6 and 2.0 
years from the primary diagnosis, respectively (IV). In multivariable analyses (Table 
8), the designed model was observed with significant prognostic impact along with 
axillary lymph node status. Independent prognostic values for the model were 
observed also among N+ and N- patients (IV).  
Verification of the designed model among luminal carcinomas and TNBCs 
indicated that the pair of securin and separase or the combination of securin, separase 
and axillary lymph node status comprised the most efficient prognostic impact 
among luminal breast carcinomas in predicting breast cancer death (HR 6.2, p 
0.0006, CI 3.2–82.6) (IV). Instead in TNBCs, no statistically significant prognostic 
impact could be observed for any of the immunohistochemically studied biomarkers 
or clinico-pathological features (IV). 
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6 Discussion 
In this study four cell cycle proteins, securin, PTTG1IP, separase and SA2, were 
characterized for their expression and assessed for their potential as biomarkers in 
predicting the prognosis of human breast cancer. The proteins were selected for 
analysis based on their known biological roles in metaphase-anaphase transition and 
on previous limited evidence of their prognostic potential in malignancy. Prognostic 
associations were derived from a maximum of 1135 breast cancer patients with 
complete clinical data and up to 22-year follow-up. 
Breast cancer is known to be a heterogenous disease with varied morphological 
and molecular features, prognosis and response to treatment (Januškevičienė and 
Petrikaitė 2019). These features present the clinician with a major problem for 
diagnostic and curative therapy. Traditionally the prediction process of breast cancer 
has been attempted with clinical and histopathological markers, i.e. tumour size, 
lymph node status, metastasis, and the immunohistochemical detection of ER, PR, 
HER2 and proliferation (Lakhani et al. 2012). Lately, this classification has been 
attempted by genetic profiling and classifying the tumour to intrinsic classifications 
(van 't Veer et al 2002, Coates et al 2015). Consequently, there is still a significant 
need for additional tools and novel biomarkers to provide with more exact prognostic 
data on the probable course of disease and the optimal treatment for each individual 
patient.  
6.1 Securin is overexpressed in human breast 
cancer (I–IV) 
In the current research, normal breast ductal epithelium was practically negative in 
securin-IHC while 8.3% of invasive breast carcinomas showed securin-
immunopositivity. Consistent with previous literature, among the positive cases, 
high extent of securin-expression was associated with aggressive clinical features, 
particularly with triple-negativity (p<0.0001) (II). 
The oncogenic properties on securin were suggested soon after the discovery of 
the protein (Dominguez et al 1998). The overexpression of securin has been 
presented in several different types of malignancies such as breast cancer (Og-
bagabriel et al 2005, Talvinen et al 2008), colorectal carcinoma (Heaney et al 2000, 
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Kim et al 2007, Zhou et al 2014), thyroid carcinoma (Boelaert et al 2001), prostate 
(Huang et al 2014), head and neck (Heikkinen et al 2016) and hepatocellular 
carcinoma (Cho-Rok et al 2006, Fujii et al 2006) while the ex-pression is very low 
in non-neoplastic tissues (Dominguez et al 1998, Zhang et al 1999). Several 
mechanisms for the overexpression of PTTG1 have been suggested, including 
genomic aberrations, somatic mutations and insufficient degradation (Bernal et al 
2002). 
In the breast, there is evidence on the essential role of securin in mammary gland 
morphogenesis. Particularly, the loss of securin expression has been seen to induce 
abnormal proliferation in ductal epithelial cells and spontaneous mammary gland 
tumorigenesis (Solbach et al 2004, Ogbagabriel et al 2005). Based on increased Pttg1 
mRNA levels in experimental animals, securin has been speculated to be regulated 
in an oestrogen-dependent manner (Yin et al 2001).  
Despite the known tumour-transforming properties and the commonly extensive 
overexpression of securin in cancer, the underlying mechanisms for its oncogenic 
properties are still largely unknown. Originally, the oncogenic properties of PTTG1 
were attempted to be explained by stimulation of the basic fibroblast growth factor 
secretion causing angiogenesis and metastatic properties (Zhang et al 1999). The 
angiogenetic function has also been shown in vivo (Ishikawa et al 2001). However, 
securin has also been suggested to promote invasion and lymph node metastasis (Yan 
et al 2009), and function in epithelial to mesenchymal transition (Yoon et al 2012). 
There is also evidence that securin both binds p53 and modulates its transcriptional 
activity, providing an-other possible pathway for tumorigenesis (Yu et al 2000). 
6.2 PTTG1IP regulates subcellular localization of 
securin in breast cancer (II, III) 
In our studies, an association was observed between the expression patterns of 
securin and PTTG1IP. Statistically, depleted PTTG1IP predicted cytoplasmic 
expression of securin (p<0.0001). Also, morphologically in IHC and double-IF, 
PTTG1IP-positivity was associated with nuclear securin expression while PTTG1IP-
negative tumours, most commonly representing TNBC, showed predominantly 
cytoplasmic securin. The current research suggests that the subcellular location of 
securin may is relevant for a proper function of the protein. The majority of breast 
carcinomas in the current study exhibited nuclear ex-pression of securin but among 
high-grade tumours and TNBCs predominantly cytoplasmic expression was 
overrepresented (p=0.002). 
In the present research (II, III), PTTG1IP immunoexpression was observed only 
in single cells of normal luminal epithelium while the majority (74.3%) of breast 
carcinomas showed a diffuse cytoplasmic PTTG1IP immunoexpression. In breast 
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carcinomas, high immunoexpression of PTTG1IP was associated with favourable 
clinical and histological features while loss of PTTG1IP was observed in aggressive 
subgroups of breast carcinomas, such as triple-negative (p<0.001) and high 
histological grade (p<0.001). 
In contrast to securin, PTTG1IP is found to be ubiquitously expressed in a wide 
variety of human tissues (Chien and Pei 2000). PTTG1IP has also been characterized 
as a tumorigenic protein (Stratford et al 2005) although this has later been questioned 
(Read et al 2011). It would appear to be capable of promoting cell growth (Li et al 
2013). In normal breast tissue, PTTG1IP is either low or non-existent (Watkins et al 
2010), being, at least in part, controlled by oestrogen (Watkins et al 2010). In breast 
cancer Pttg1IP is overexpressed (Watkins et al 2010) and has also been shown to 
promote invasion (Watkins et al 2010, Watkins et al 2016). Literature concerning 
the subcellular localization of securin in neoplasia is sparse although the cytoplasmic 
securin has been speculated in gastric (Xu et al 2016), testicular (Pierconti et al 
2015), oesophageal (Ito et al 2008) and pancreatic carcinomas (Lin et al 2013), as 
well as brain tumours (Salehi et al 2013). According to literature, the subcellular 
localization of securin in non-neoplastic cells appears to be cell type-dependent (Mu 
et al 2003, Cai et al 2014). In normal luminal cells of the breast, securin is located in 
the nucleus of the cell. During the cell cycle, however, securin is degraded and then 
resynthesized in the cytoplasm. In neoplasia, the regulation of subcellular expression 
of securin is not settled. However, there is evidence that the translocation of the 
protein from the cytoplasm to the nucleus is mediated by a PTTG1IP (Chien and Pei 
2000) although their precise roles remain undefined (Read et al 2017).  
6.3 SA2 expression is lost in poorly differentiated 
breast carcinomas (II) 
Among the core cohesion complex, RAD21 has emerged as the key biomarker the 
expression of which has been described for breast, ovarian, bladder and lung 
carcinomas (Rhodes et al 2004). Instead, very little has been published on the 
expression of SA2 in breast cancer and, therefore, SA2 was chosen as the target 
protein for investigating the regulation of cohesin-dependent sister chromatid 
separation in Study II. In the immunoanalysis, SA2 showed a distinct expression 
pattern. SA2 was found to be strongly and uniformly expressed in benign breast 
luminal epithelium and low-grade carcinomas while SA2 expression was absent in 
high-grade carcinomas (p=0.02). 
The regulation of SA2 expression in breast cancer has not been settled although 
alterations in gene and protein expressions as well as targeting microRNAs have 
been speculated (Yan et al 2012). 
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6.4 Securin, PTTG1IP, separase and SA2 predict 
survival of breast cancer patients. (I–IV) 
In the present material, the immunoexpression of each of the studied proteins was 
significantly associated with breast cancer-specific survival. High expression for 
both nuclear securin and separase predicted increased mortality whereas 
immunoexpressions for cytoplasmic securin, PTTG1IP and SA2 were adversely 
related to disease outcome. The prognostic impact of PTTG1IP and separase were 
intensified after combination with securin. 
The prognostic associations of securin have been previously reported. 
Overexpression of securin has been demonstrated in breast carcinomas with 
aggressive morphology, metastatic spread and relapse (Solbach et al 2004, 
Ogbagabriel et al 2005). In clinical materials, securin overexpression has been 
associated with aggressive course of disease, nodal involvement and distal 
metastases, as well as resistance for radiation and cytotoxic therapy (Tong et al 2011, 
Grizzi et al 2013, Liao et al 2014). In addition, the expression of securin in the stroma 
surrounding breast cancer has been shown with prognostic impact (Bacac et al 2006). 
Moreover, the present patient material has previously been used to demonstrate the 
prognostic value of securin in breast cancer (Talvinen et al 2013, Gurvits et al 2017). 
Concerning other malignancies, several papers report on the association of securin 
overexpression with disease outcome in gastric, oesophageal, brain and endocrine 
tumours (Salehi et al 2013, Zhang et al 2014, Xu et al 2016, Romero Arenas et al 
2018).  
The prognostic value of separase has been previously acknowledged. However, 
the results are incomprehensive and partly contradictory. Previous literature reports 
on reduced and increased expression of separase in malignant disease (Kumar 2017). 
In humans, overexpression of separase expression has been observed in several 
malignancies, e.g. in breast and prostate carcinomas although the results are partly 
based on relatively small materials (Meyer et al 2009, Gurvits et al 2017). Separase 
overexpression has also been observed in association with aneuploidy DNA content 
in human breast cancer (Zhang et al 2008, Meyer et al 2009). In breast cancer, 
overexpression of separase has been observed as a characteristic of luminal B 
carcinomas (Finetti et al 2014). ESPL1 mutations causing loss of separase expression 
have been reported from renal and pulmonary carcinomas (Sak et al 2008, Gao et al 
2019). Also, Separase mRNA levels have been associated with poor histological 
differentiation and mortality in breast carcinomas (Mukherjee et al 2014).  
In the present material, the combined prognostic value of securin and separase 
was evidenced based on data from a total of 1135 breast cancer patients with 
complete clinical information and up to 22-year follow-up. Securin and separase 
combined into a model together with cdk1 showed equivalent prognostic value in 
predicting breast cancer mortality as axillary lymph node status. The results 
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suggested prognostic impact for our model also among node-positive and node-
negative patients. Securin, separase and nodal status in combination predicted 
outcome of breast cancer also for luminal breast carcinomas, but not for TNBC. In 
breast cancer, multigene profiling assays (Xin et al 2017) have been established for 
clinical use to define breast cancer subtypes with individual molecular pathways 
predicting survival and/or treatment response. Simultaneously, various 
multiparametric prognostic models based on gene and protein expression are being 
developed for different clinical purposes, such as predicting disease recurrence 
(Lundberg et al 2017) or treatment response (Kurebayashi et al 2011). Recently, 
ESPL1 has been involved in a signature to predict the outcome of ER-positive breast 
cancer and response to neoadjuvant therapy in breast carcinomas (Buechler et al 
2019a, Buechler et al 2019b). PTTG1 has also been combined into a prognostic 
signature predicting survival of papillary renal cell carcinoma (Gao et al 2019).  
Concerning PTTG1IP, the evidence of prognostic impact is sparse and partly 
contradictory. However, the role of PTTG1IP in tumorigenesis through regulating 
p53 activity has been established in a number of reports (Read et al 2014, Read et al 
2016). Most of the clinical prognostic trials involve thyroid cancer where PTTG1IP 
overexpression has been associated with poor prognosis (Hsueh et al 2013, Read et 
al 2017) and tumour recurrence (Stratford et al 2005). Also, in colorectal cancer, 
PTTG1IP has been associated with unfavourable outcome due to increased 
extramural vascular invasion, genetic instability and somatic TP53 mutations (Read 
et al 2016). 
Research on the possible prognostic value of cohesin is sparse and mostly deals 
with SCC1/RAD21 subunits and not SA2. Only single papers report on the 
prognostic value of SA2 in cancer and the results are controversial. The loss of SA2 
expression was detected in association with increased disease mortality in invasive 
urothelial carcinomas (Solomon et al 2013). Instead, in pancreatic carcinomas SA2 
expression has been associated with higher survival rates, whereas the loss of 
expression predicted positive response to adjuvant chemotherapy (Evers et al 2014). 
Previously, SA2 has also been studied in acute myeloid leukaemia without detected 
significant prognostic associations (Thol et al 2014). 
6.5 Benefits and limitations of the research (I–IV) 
The present study is based on a relatively large patient cohort with a well-established 
clinical data and a long-term follow-up time reaching up to 22 years after diagnosis 
(mean 10 years). The cases originate from the era of national mammographic 
screening and, therefore, can be expected to be representative of the population. 
According to literature, the comparative number of histological grades vary in 
different breast cancer materials with grade I representing 11-38%, grade II 36-49% 
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and grade III 19-46% of the cases (Rakha et al 2010). In our material the distribution 
of the different grades was well in line with the literature being 27%, 50% and 23% 
for grades I to III, respectively. Similarly, the distribution of the different histological 
diagnoses and subgroups of intrinsic classification correspond to the prevalence 
presented for breast cancer in literature (Dai et al 2015).  
The tissue samples of the patient material were collected from among the 
diagnostic specimen of clinical pathology practice. Due to the retrospective approach 
of the study, it may be speculated that the immunohistochemical detection of the 
studied proteins may have been compromised by the long archival time. Recently, 
the emerge of biobanks has enable conducting wide-scale research based on large 
collections of biological specimens and correlated clinical data (Paskal et al 2018). 
For IHC, the specimens were collected into TMAs. TMAs are generally 
considered to improve the efficiency and cost-effectiveness of IHC. In addition, 
immunoevaluations in TMAs have been associated with high intra-and interobserver 
reproducibility (van Zwieten 2013). According to literature, immunohistochemistry 
on TMAs has been shown to have high concordance with whole tumour sections of 
the original tissue (Dixon et al 2015). Thus, results obtained from TMAs can be 
considered reliable, providing that the number of cases in the cohort is sufficient 
(Pinder et al 2013).  
Intratumor heterogeneity is a common feature of malignancies and concerns 
particularly proliferation-related markers which, according to literature, show 
highest expression at the infiltrative front of tumours (Beliën et al 1999). In an 
attempt to manage the heterogeneity of the immunoexpressions, the TMAs on the 
present study were designed to include duplicate cores from every tumour. Based on 
literature and our own experience, however, the expression of the studied proteins 
did not considerable vary between different tumour compartments. Moreover, in 
order to ensure adequate representation of the studied protein in the tumour tissue, 
the interpretation of all immunostainings was started by examining whole tumour 
sections. In statistical analyses, the higher value obtained from the two cores was 
chosen for prognostic analyses further minimizing the influence of heterogeneous 
expression patterns.  
Proteins are involved in virtually every biological phenomenon both in the 
normal and in neoplastic tissues. Genomic data is often insufficient in explaining 
biological processes while proteomic studies may provide understanding on disease 
processes, such as cancer, and identify means for therapeutic interventions. Since the 
last decades, the combination of IHC on TMAs has become an established method 
for detection and validation of novel biomarkers in cancer research (Hao et al 2004). 
IHC is a method of experimental as well as clinical practice and serves to correlate 
expression data to the morphological interpretation of tissues, and subcellular 
structures.  
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6.6 Securin, PTTG1IP, separase and SA2 have 
clinical relevance in breast cancer (I–IV) 
Breast cancer is the most common malignancy and cause of cancer deaths among 
women in both Finland and worldwide. It has been estimated, that every 8th Finnish 
woman will be diagnosed with breast cancer during her lifespan (www.cancer.fi). 
Due to early detection and improvements in the diagnostic and therapeutic approach 
the current 5-year relative survival rate over 90 % (Finnish Cancer Registry 2019) 
Still, breast cancer is the most prevalent cancer in Finnish women and remains the 
major cause of cancer mortality. In addition, breast cancer and its treatment compose 
a considerable challenge for the quality of life among the increasing group of disease 
survivors. The high incidence of breast cancer together with being the leading cause 
of death all around the world has sparked the pursuit for detection of new and more 
efficient biomarkers for diagnostic, prognostic and predictive tools.  
The current clinical prognostic and predictive parameters provide limited 
possibilities for prognostic classifications and categorization of carcinomas for 
treatments, leading to possible over- or undertreatment of individual patients. There 
are also limited means to predict the outcome of the treatments and guide the clinical 
decision-making progress. The high clinical relevance of breast cancer has resulted 
in the increasingly active publication. Still, only single biomarkers are recommended 
in clinical practice guidelines across (Fan 2013). 
Proliferation has traditionally been used as a prognostic marker. The 
immunohistochemical evaluation of Ki-67 has traditionally been used as a tool for 
this evaluation. Also, the mitotic count in breast cancer cells is used in assessing the 
grade of the tumour. Metaphase-anaphase transition comprises one of the critical 
steps in the cell cycle and it is controlled by a complex network of regulators. The 
present study shows evidence that securin expression may serve as a strong and 
independent prognosticator of breast cancer outcome. According to the hallmarks of 
cancer, uncontrolled proliferation is one of the waypoints on the malignant 
progression of the cells (Hanahan and Weinberg 2011). With uncontrolled and 
uncoordinated cell proliferation the risk of checkpoint failure and chromosomal 
instability increases, leading to aneuploidy. Breast cancer is often known to harbour 
severe chromosomal instability, especially in triple-negative tumours.  Interestingly, 
although several cell cycle proteins are included in gene panels predicting the 
behaviour of breast cancer, very few mutations have been found in the genes coding 
these proteins (Yuan et al 2006). The answer does not appear to be in single 
nucleotide pleomorphisms either (Brendle et al 2009). This leads to the conclusion 
that the answer lies somewhere in the epigenetic regulation, such as promoter 
methylation, of these proteins (Park et al 2007).  
Recently, breast cancer treatment is experiencing a shift towards minimal 
surgery. As an example, lymphatic mapping and sentinel node investigations as 
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methods of evaluating local control of the disease and criteria for staging are 
currently being substituted by radiological evaluation of metastatic burden in the 
axilla (Nurudeen and Hunt 2018). Likewise, the increased use of neoadjuvant 
therapies results in more patients receiving systemic therapy before surgical removal 
of the tumour. These new developments in breast cancer therapy would greatly 
benefit from identification of biomarkers or biomarker signatures to individually 
predict the prognosis of the disease and the potential effectiveness of the treatments 
(Selli and Sims 2019). These developments emphasize the need for increasingly 
effective and progressively more targeted systemic therapies, also applying 
regulation of the cell cycle.  
There is in vivo evidence, that manipulating the cell cycle checkpoint proteins 
provokes a massive chromosome loss and apoptosis, even in the setting of initially 
highly chromosomally instable cancer cells (Kops et al 2004). Only partially 
disturbing the chromosomal checkpoint resulted in minor chromosomal errors, but 
not cell lethality, and an increased sensitivity to the cytotoxic drug, taxol (Janssen et 
al 2009) or reversing cytotoxic drug resistance in the cells (Lee et al 2004). These 
results have opened the possibility of using the checkpoint proteins as possible 
druggable targets for cancer treatment. 
Recently, securin has been suggested with potential as a therapeutic target for 
breast cancer (Grizzi et al 2013), particularly in case of ER-positive disease (Ghayad 
et al 2009). In addition, it has been suggested that depleting securin from the cells 
enhances radiosensitivity and induces senescence in the cancer cells, possibly due to 
disruption of the DNA double strand break repair function of securin (Chen et al 
2010). Examining non-small cell lung carcinoma cells and nude mice Kakar et al 
(2006) targeted PTTG1 mRNA by using small interfering RNA (siRNA) (Kakar and 
Malik 2006). This silencing resulted in down-regulation of PTTG1 and reduced 
tumour growth in vitro and in vivo. These results have been repeated with 
hepatocellular carcinoma, both in vitro and in vivo (Cho-Rok et al 2006). In addition 
to siRNAS, similar results have been obtained using different methods. Mo et al. 
(2009) utilized the interaction of securin and PTTG1IP and created an engineered 
ubiquitin-protein ligase fusion protein with PTTG1IP, targeting overexpressed 
securin in both human cervical cancer line (HeLa cells) and activated monkey 
fibroblasts (COS-7) cells. The result was downregulation of securin and inhibition 
of cell growth (Mo et al 2009). Cho-Rok et el. (2006) targeted securin using an 
adenovirus-mediated transfer of siRNA, reducing tumour growth of hepatocellular 
carcinoma both in vitro and in vivo (Cho-Rok et al 2006). As clinical trials for 
adenovirus virotherapy are already taking place, this presents a promising treatment 
strategy.  
In addition to securin, also separase has been suggested as a potential future 
molecular target for cancer therapy (Kumar 2017) other cell cycle proteins have also 
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been presented as possible predictive biomarkers or targets for cancer treatment. 
Ruppenthal et al (2018) have speculated that an increase in separase activity might 
be potential marker in identifying the malignant transformation of myelodysplastic 
syndrome to leukaemia (Ruppenthal et al 2018). Also, sepins - separase inhibitors – 
have been introduced as a potential novel cancer treatment, inhibiting tumour cell 
growth both in vitro and in vivo.  Sepin-1 has been shown to inhibit the growth of 
human cancer cell lines and breast cancer xenograft tumours in mice by inhibiting 
cell proliferation and inducing apoptosis (Zhang et al 2014). The expression level of 
separase has been shown to predict the sensitivity to sepins in both cancer cell lines 
and tumours  
Concerning SA2, it has also been shown that glioblastoma cells with harbouring 
mutations on the SA2 coding STAG2 gene are more sensitive to PARP inhibitors 
(Bailey et al 2014). In melanoma cells loss of STAG2 function increased the 
resistance to BRAF inhibition (Che-hung Shen et al 2016). In pancreatic ductal 
adenocarcinoma is affected more by chemotherapy is more efficient if the expression 
of SA2 is low (Evers et al 2014). 
Based on our results, cell cycle proteins, particularly securin and separase, could 
be used to predict the prognosis of breast cancer patients and possible used to 
modulate treatment decisions. However, further research is still required. In the 
future, there are still interesting research avenues such as the association of p53 with 
securin in breast cancer yet to revealed.  
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7 Conclusions 
In this thesis, the immunohistochemical expression of and the subcellular location of 
securin, PTTG1IP, separase and SA2 has been evaluated in association with the 
prognosis of breast cancer.  
1.  The expression of securin, PTTG1IP, separase and SA2 in breast cancer 
differs from their expression in normal breast epithelium. In breast cancer, in-
creased expression of securin and separase is associated with aggressive 
tumour morphology while the expression of PTTG1IP and SA2 is lost in 
poorly differentiated tumours. In high-grade breast carcinomas, the 
subcellular expression of securin shifts from the nuclear to cytoplasmic while 
PTTG1IP expression is simultaneous lost.  
2.  Securin, separase, PTTG1IP and SA2 predict the prognosis of breast cancer. 
The strongest prognosticators are securin and separase which predict at least 
doubled breast cancer mortality. 
3.  Among all breast carcinomas and luminal carcinoma, securin and separase 
alone and combined into prognostic models show independent prognostic 
value exceeded only by the impact of axillary lymph node status. 
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